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ABSTRACT  
The prevalence of type 2 diabetes (T2D) has increased worldwide during the last decades. 
Lifestyle factors such as obesity are strongly associated with insulin resistance and T2D. 
Increasing evidence suggests that dysregulations in lipid influx, storage, or triacylglycerol 
(TAG) lipolysis have significant impact on insulin sensitivity and glucose homeostasis in 
skeletal muscle. Moreover, it has been suggested that insulin resistance in obesity and T2D 
is associated with accumulation of lipids in skeletal muscles. Much focus has been on the 
possibility of increasing lipid utilization by exercise or pharmacologically to avoid ectopic 
lipid accumulation in muscle. The nuclear receptor peroxisome proliferator-activated 
receptor į (PPARį) is shown to be an important regulator of skeletal muscle lipid 
metabolism, highlighting the potential utility of this receptor as a therapeutic option for 
treatment of T2D. This thesis aimed to study regulation of energy metabolism related to 
obesity and T2D in cultured human skeletal muscle cells by PPARį activation and in vitro 
exercise. The lipid droplet (LD)-associated protein perilipin 2 (PLIN2) is one of the PPARį 
target genes, and to study the functional role of PLIN2 and LDs in skeletal muscle energy 
metabolism we also examined myotube cultures established from PLIN2+/+ and PLIN2-/- 
mice. 
A reduced insulin response was observed in myotubes from severely obese donors (BMI  
40 kg/m2) with established T2D confirming that myotubes maintain their diabetic phenotype 
in culture. Diabetic myotubes showed also lower lipid accumulation and fatty acid (FA) 
incorporation into TAG, as well as higher lipolysis with lower ability to increase oxidation 
of lipids with increased FA availability, compared to myotubes from non-diabetic donors 
with similar BMI. Chronic low-frequency electrical pulse stimulation (EPS), as an in vitro 
model of endurance exercise, was able to improve insulin sensitivity in insulin-resistant 
myotubes from diabetic donors. EPS increased lipid oxidation and mitochondrial content in 
myotubes from lean non-diabetic subjects, but not in myotubes from severely obese subjects. 
Furthermore, EPS increased the mRNA expression of the myokine interleukin-6 in 
myotubes from both lean and severely obese non-diabetic subjects. The principal effect of 
PPARį activation was to increase mitochondrial FA oxidative capacity, and in contrast to 
the effect of EPS, the effect of PPARį on lipid metabolism was not different between 
myotubes from the various donor groups. Increase in PLIN2 gene expression after PPARį 
activation was not accompanied with an effect on number of LDs or on lipolysis, while 
ablation of PLIN2 resulted in myotubes with reduced number of LDs and reduced 
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accumulation of TAG and higher lipolysis. Both PPARį activation and ablation of PLIN2 
resulted in a metabolic shift in energy metabolism from utilization of glucose towards FAs. 
Furthermore, neither ablation of PLIN2 nor activation of PPARį had any impact on insulin-
stimulated responses despite of increased oxidative capacity for FAs. 
The results presented in this thesis suggest that myotubes to some extent retain the 
phenotype of their donors, and that responses to EPS, but not to PPARį, reflected the in vivo 
characteristics of the donors. While both exercise in vitro (EPS), activation of PPARį and 
lack of PLIN2 increased lipid oxidation, only EPS had any impact on the insulin-stimulated 
responses, whereas both PPARį activation and increased FA availability through PLIN2 
ablation shifted the cells from glucose to lipid metabolism.  
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INTRODUCTION 
Energy metabolism in skeletal muscle 
Skeletal muscle constitutes about 40% of the body weight in non-obese individuals, and is 
the largest insulin-sensitive organ, accounting for more than 80% of insulin-stimulated 
glucose disposal, and is therefore the quantitatively the most important site for insulin 
resistance [1-3]. At resting, skeletal muscle accounts for about 30% of the metabolic rate [4]. 
Moreover, it is also the quantitatively most dominant tissue with respect to lipid metabolism 
and the largest glycogen storage organ [5, 6]. Factors regulating fatty acid (FA) oxidation 
and mitochondrial function capacity are likely to directly affect muscle metabolic function 
and, because of its large contribution to total body mass, to have a significant impact on 
whole-body energy metabolism. Thus, the critical role that skeletal muscle plays in glycemic 
control and metabolic homeostasis makes it an organ of particular interest in obesity and 
type 2 diabetes (T2D). 
Under resting conditions, glucose uptake is considered as the rate-limiting step for glucose 
utilization [7], and is mainly mediated by glucose transporter (GLUT) 1 and 4 in skeletal 
muscle [8, 9]. GLUT1 appears to be involved mainly in basal glucose uptake [10], whereas 
in response to insulin stimulation or contraction, GLUT4 is translocated from intracellular 
vesicles to the cell surface of skeletal muscle cells, resulting in an increase in glucose uptake 
[11-14]. The canonical insulin-signaling pathway is triggered by activating of insulin 
receptor tyrosine kinase, leading to phosphorylation of substrate proteins and their 
recruitment and activation of phosphatidylinositol 3-kinase (PI3-kinase), which in turn 
triggers phosphorylation of Akt (PKB) [15]. Thus, Akt is the principal insulin-regulated 
signal transducer for GLUT4 translocation in response to insulin [16]. Once glucose has 
been transported across the plasma membrane, it is phosphorylated to glucose 6-phosphate 
(G-6-P) by hexokinase and proceed to glycolysis, generating pyruvate, ATP and NADH 
(Figure 1). Alternatively, G-6-P can be converted to glycogen for storage, which is 
mediated by glycogen synthase [17]. In the case of excessive energy supply and the limited 
ability to store glycogen in skeletal muscle, most excess glucose is converted to lipids 
through lipogenesis [18]. De novo lipogenesis occurs in skeletal muscle, but only to a small 
extent [19]. Pyruvate, either from plasma glucose or from stored glycogen, can proceed to 
oxidation in mitochondria via decarboxylation to acetyl-CoA, which is mediated by the 
pyruvate dehydrogenase complex (PDC) [20].  
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Free fatty acids (FFAs) are taken up from the circulation into muscle either by passive 
diffusion or by protein-mediated transport (Figure 1). The major proteins regulating muscle 
FA uptake are FA translocase (FAT/CD36), plasma membrane-associated FA-binding 
protein (FABPpm) and a family of FA transport proteins (FATP1-6) [21, 22], where CD36 
and FATP4 are considered quantitatively the most important in skeletal muscles [23, 24]. 
Once inside the cells, FAs are reversibly bound to the abundantly expressed cytoplasmatic 
FABP, which acts as a sink for the incoming FAs to protect against lipotoxic accumulation 
of free FAs and traffics FAs throughout cellular compartments [25].  FAs are activated to 
FA-CoA (acyl-CoA) through a reaction mediated by acyl-CoA synthetase (ACSL) [26]. 
Acyl-CoA-binding protein (ACBP) acts as an intracellular carrier of FA-CoA, where FA-
CoA can be oxidized in mitochondria for ATP production, esterified to monoacylglycerol 
(MAG) and diacylglycerol (DAG) and stored as triacylglycerol (TAG) in lipid droplets 
(discussed in more details under “Dynamics in skeletal muscle lipid pools”, page 9), 
incorporated into phospholipids or metabolized to lipid second messengers [27, 28]. The fate 
of FA is influenced by the concentration of the incoming FA, the type of FA, the muscle 
fiber type, the hormonal milieu, and the energy requirements of the muscle [25]. Long-chain 
FA-CoA can be oxidized after mitochondrial transport as acyl-carnitine, which is facilitated 
by carnitine palmitoyltransferase 1 (CPT1) located on the outer mitochondrial membrane 
and CPT2 located on the inner mitochondrial membrane [29]. CD36 is also found in the 
mitochondrial membrane, and have been suggested to work in cooperation with CPT1 [30, 
31]. Inside the mitochondrial matrix, FA-CoA is metabolized through the ȕ-oxidation 
pathway to acetyl-CoA. Thereafter, acetyl-CoA from both ȕ-oxidation and glycolysis enters 
the TCA-cycle (Figure 1). The regulation of FA oxidation has previously been attributed 
primarily to transport of FAs across the mitochondrial membranes and, specifically, by 
reduced malonyl-CoA inhibition of CPT1 derived from acetyl-CoA from glycolytic pathway 
catalyzed by acetyl-CoA carboxylase (ACC2) in oxidative tissues [29]. However, recent 
work has challenged this dogma, suggesting that the regulation of skeletal muscle FA 
oxidation is a more complicated process and involves multiple regulatory sites, including FA 
transport across the membrane, binding and transport of FAs in the cytoplasm, LD formation 
and degradation, FA transport across the mitochondrial membranes and potential regulations 
within the ȕ-oxidation pathway, TCA cycle and electron transport chain [32-34]. 
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Figure 1. Energy metabolism in skeletal muscle. Glucose is transported into cells through glucose 
transporters (GLUT) and is stored either as glycogen or utilized through process of glycolysis to 
yield pyruvate. GLUT4 is translocated from intracellular vesicles to the cell surface through 
activation of the insulin pathway. Uptake of fatty acids (FAs) is facilitated by different transport 
proteins (FAT, FATP and FABPpm). Intracellular FAs are bound to cytosolic FA binding proteins 
(FABPc) and activated to FA-CoA by acyl-CoA synthetase (ACSL). Acyl-CoA-binding protein 
(ACBP) acts as an intracellular carrier of FA-CoA. Under conditions of excess energy supply, FA-
CoAs may be incorporated into complex lipids as diacylglycerol (DAG), triacylglycerol (TAG) and 
phospholipids (PL), and assembled in lipid droplets (LDs) for storage via the action of 
monoacylglycerol acyltransferase (MGAT) and diacylglycerol acyltransferase (DGAT). Upon 
energy demand, TAG, DAG and monoacylglycerol (MAG) are hydrolyzed by adipose triglyceride 
lipase (ATGL), hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MGL) to FAs. FA-
CoAs from both exogenous and endogenous derived FAs are used as fuel and transported into 
mitochondria as acyl-carnitine via carnitine palmitoyltransferase (CPT) 1 and 2, and thereafter 
metabolized through ȕ-oxidation, yielding acetyl-CoA, which then enters the TCA-cycle. Pyruvate, 
either from plasma glucose or from stored glycogen, can enter the mitochondria via decarboxylation 
to acetyl-CoA through the action of pyruvate dehydrogenase complex (PDC). Citrate that escapes 
from TCA-cycle can be converted to acetyl-CoA in the cytosol by ATP citrate lyase (ACL), and 
thereafter to malonyl-CoA by acetyl-CoA carboxylase (ACC). Malonyl-CoA decarboxylase (MCD) 
catalyzes the reverse reaction and converts malonyl-CoA to acetyl-CoA. Malonyl-CoA can be 
converted to FAs by the action of FA synthase (FASN) and FAs can be further elongated and 
desaturated by elongases and stearoyl-CoA desaturases (SCD), respectively. Malonyl-CoA is a 
potent inhibitor of CPT1, and can therefore inhibit entry and oxidation of FAs in the mitochondria. 
FAs are able to suppress glucose oxidation through inhibition of PDC by pyruvate dehydrogenase 
kinase isozyme 4 (PDK4) and by acetyl-CoA, as well as inhibition of glycolytic enzymes by 
cytosolic citrate. The mutual inhibition of substrate metabolism is often referred as Randle cycle (FA 
suppresses glucose oxidation) and reverse Randle cycle (glucose suppresses FA oxidation). 
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Dynamics of skeletal muscle lipid pools 
Approximately 50-60% of the FAs taken up by the muscle cells are stored as TAG in lipid 
droplets (LDs), referred as intramyocellular TAG (IMTG) [35]. The conversion of FA-CoA 
and MAG to DAG is mediated by monoacylglycerol acyltransferase (MGAT), and 
conversion of DAG to TAG is mediated diacylglycerol acyltransferase (DGAT) 1 or 2 [36] 
(Figure 1). Besides TAG, LDs also contain DAG, cholesteryl ester (CE) and free cholesterol, 
and they are surrounded by a monolayer of phospholipids (PL) and LD-associated proteins 
(e.g. perilipins) [37, 38]. The mammalian genome encodes for five perilipin (PLIN) genes, 
and additional splice variants, with different tissue expression patterns [39]. In addition, 
PLINs differ also in size, affinity to LDs, stability when not bound to LDs, and 
transcriptional regulation. Positioned at the lipid LD surface, PLINs manage access of 
lipases to the lipids within the LD core and thereby regulating LD size and turnover [38]. In 
human skeletal muscle, all five PLINs are present at mRNA level where PLIN2 (also known 
as adipocyte differentiation-related protein or adipophilin) is one of the most abundantly 
LD-associated proteins expressed [40]. Further, in human muscle biopsies, the majority of 
the LDs (~ 60%) were shown to be covered by PLIN2, and PLIN2 content was also higher 
in oxidative type I muscle fibers compared to glycolytic type II fibers [41]. Furthermore, 
PLIN2 is shown to be more abundant in woman than in men, consistent with higher IMTG 
content observed in female skeletal muscle [42].  
Upon energy demand e.g. during exercise, the enzymatic degradation of the esterified 
neutral lipids in the LD-core into single lipid species such as FAs or glycerol depends on 
active recruitment of lipases to the LD surface. Adipose triglyceride lipase (ATGL) is 
considered to be the first step in TAG catabolism [43], generating DAG, which is 
subsequently degraded by hormone-sensitive lipase (HSL) [44]. In the final step, MAG is 
degraded to glycerol and FA by monoacylglycerol lipase (MGL) (Figure 1) and thus 
providing FAs that can be oxidized in mitochondria. Moreover, lipase-mediated TAG 
hydrolysis can also generate lipid ligands for peroxisome proliferator-activated receptors 
(discussed in more details under “Role of peroxisome proliferator-activated receptors 
(PPARs) on energy metabolism in skeletal muscle”, page 12). Other potentially important 
proteins in the regulation of breakdown of IMTG are CGI-58 [45] and G0/G1 switch genes 2 
(G0S2) [46], which are identified as coactivator and inhibitor of ATGL, respectively. 
Interestingly, during contraction-induced muscle lipolysis, ATGL and CGI-58 are strongly 
associated and they work together with PLIN proteins to regulate lipolysis [47]. HSL 
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activity is mostly regulated by phosphorylation such as phosphorylation on serine 660 [48]. 
LDs in oxidative muscle are often close to mitochondria, thereby maintaining coupling of 
lipid storage with consumption of lipids as fuel which appears to be important for efficient 
energy utilization [37]. 
 
Metabolic flexibility of skeletal muscle  
The ability of skeletal muscle to switch between substrates for fuel depending on substrate 
availability, exercise intensity and physiological conditions represent an important feature in 
healthy skeletal muscle and is called metabolic flexibility [49, 50]. In the fed state, increased 
availability of plasma glucose stimulates glucose oxidation and FA synthesis, whereas FA 
oxidation increases both during fasting and sustained exercise [51, 52]. The inhibition of 
glucose oxidation by FAs is often referred as “Randle cycle” [53]. This is mediated by 
inhibition of several glycolytic steps. Pyruvate dehydrogenase kinase isozyme 4 (PDK4), the 
dominant isoform in skeletal muscle inhibits PDC by phosphorylation, and thereby 
switching the fuel source from glucose to FA [54] (Figure 1). Further, excess production of 
citrate from enhanced FA oxidation escapes from mitochondria and inhibits the rate-limiting 
enzyme of glycolysis, 6-phosphofructo-1-kinase, leading to an increase in G-6-P, which 
eventually inhibits hexokinase and leads to reduced glucose uptake and oxidation [32, 55]. 
The opposite situation, where glucose suppresses FA oxidation, is often referred as “reverse 
Randle cycle” [56]. Citrate escaped from oxidation of glucose is transported back to the 
cytosol, where it is converted to acetyl-CoA by ATP citrate lyase (ACL), which in turn is 
converted to malonyl-CoA by ACC. As stated above, malonyl-CoA inhibits CPT1 and 
thereby entry and oxidation of FAs in mitochondria [56, 57] (Figure 1). 
Loss of ability to switch easily between glucose and lipid oxidation is termed metabolic 
inflexibility [50], and is associated with reduced lipid oxidation, and thereby promotes 
accumulation of lipids in skeletal muscle [58], which can interfere with insulin signaling and 
function (discussed in more details under “Insulin resistance, obesity and type 2 diabetes”, 
page 19). Obesity, insulin resistance and T2D are linked to reduced lipid oxidation during 
fasting and impaired postprandial switch from lipid to glucose oxidation [59], and this 
inflexibility is also observed in individuals with impaired glucose tolerance [60], suggesting 
that inflexibility plays an role in the early development of T2D. In fact, cultured skeletal 
muscle cells (myotubes) established from subjects with T2D, as well as those from obese 
subjects, have reduced capacity to oxidize FAs compared to cells from lean subjects [61, 62]. 
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Furthermore, metabolic flexibility of substrate oxidation is also preserved in cells when 
grown in culture, suggesting that metabolic switching is an intrinsic property of skeletal 
muscle [63]. Metabolic switching of myotubes in vitro is referred as suppressibility, 
adaptability and substrate-regulated flexibility [63, 64]. Suppressibility is defined as the 
ability of the cells to suppress FA oxidation by acute addition of glucose, and adaptability is 
defined as the capacity of the cells to increase FA oxidation upon increased FA availability 
[63], whereas substrate-regulated flexibility is defines as the ability to increase FA oxidation 
when changing from a high glucose, low FA condition (“fed state”) to a high FA, low 
glucose condition (“fasted state”) [64]. Nevertheless, metabolic inflexibility could be due to 
both intrinsic and extrinsic (induced) factors and the molecular mechanism underlying 
metabolic inflexibility remains to be revealed. 
 
Skeletal muscle fiber types 
Skeletal muscles comprise a variety of muscle fiber types with different contractile and 
metabolic properties [65, 66]. Based on the determination of predominant myosin heavy 
chain (MHC) isoforms, it has been established that rodents have four fiber types termed I, 
IIa, IIx and IIb (respective genes, MYH7, MYH2, MYH1 and MYH4), while human 
muscles contain three fiber types; I, IIa, and IIx [67, 68] where the slow-twitch type I fibers 
are associated with higher mitochondrial content compared to fast-twitch type II fibers [69], 
and higher GLUT4 protein expression [70, 71]. Furthermore, type I fibers mainly depend on 
oxidative (aerobic) and type IIx fibers on glycolytic (anaerobic) pathways for ATP 
production, while type IIa fibers display an intermediate phenotype [67]. Therefore, a higher 
composition of type I fibers in muscle have been reported to be associated with increased 
insulin responsiveness [72]. In fact, individuals with insulin resistance or T2D have a 
distinct muscle phenotype with decreased type I fibers [73, 74], accompanied by decreased 
GLUT4 expression within the type I fibers [75]. However, this view has been challenged by 
the finding that altering the fiber composition to muscles towards type IIb fibers in mice also 
improves glucose homeostasis and insulin action [76]. The mechanisms involved in muscle 
fiber type switching are complex and not known in detail, but transcription factors such as 
myocyte enhancer factor 2 (MEF2) [77] and its target gene, peroxisome proliferator-
activated receptor gamma coactivator 1 alpha (PGC1Į) [78], have been shown to be 
implicated in control of slow fiber type program (discussed in more details under “Exercise 
and energy metabolism in skeletal muscle”, page 14).  
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Role of peroxisome proliferator-activated receptors (PPARs) in energy metabolism in 
skeletal muscle  
Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent nuclear receptors 
that belong to the superfamily of nuclear transcription factors. PPARs are activated by a 
diversity of molecules including FAs and FA metabolites. The PPAR family consists of 
three subtypes encodes by three genes; PPARĮ, PPARį/ȕ, and PPARȖ [79]. The PPARs 
share a high degree of functional and structural similarities, and specific activities of the 
PPARs is depending on their tissue distribution, ligand binding and the recruitment of 
coactivators and corepressors [80]. PGC1Į, which is one of the best described coactivators 
of PPAR, is able to activate all three PPAR subtypes, as well as other transcription factors 
such as MEF2 [81]. A heterodimer of retinoid X receptor and PPAR bind to the PPAR-
responsive element in specific target genes, but also interacts with other transcriptional 
regulatory pathways [65]. PPARs regulate transcription of a large variety of genes involved 
in energy metabolism, proliferation and differentiation [65, 82]. Additionally, PPARs have 
emerged as key regulators of inflammatory and immune responses [80].  
PPARĮ is abundantly expressed in tissues with high FA catabolism such as liver, heart and 
skeletal muscle [65, 82, 83]. PPARĮ in the liver upregulates genes involved in FA uptake, 
FA activation and FA transport into the mitochondria, and mitochondrial FA oxidation, 
reducing FAs ability to become integrated into plasma lipoproteins carrying TAG. 
Consequently, PPARĮ agonists such as fibrates are used to treat dyslipidemia [84]. PPARȖ 
is primarily expressed in white adipose tissue (WAT) promoting adipogenesis and lipid 
synthesis, but it is also expressed in immune cells [79]. PPARȖ plays a critical role in the 
differentiation of pre-adipocytes to adipocytes, where WAT serves as a safe place to store 
excess energy as TAG to avoid lipid deposition in other tissues, and thus contributes to 
preserve insulin sensitivity. In addition, PPARȖ plays an important anti-inflammatory role in 
macrophages [80]. Thus, synthetic ligand PPARȖ agonists (thiazolidinediones or glitazones) 
work as insulin sensitizers and are used in the treatment of T2D [84]. 
 
Peroxisome proliferator-activated receptor į/ȕ  
PPARį (also known as ȕ) is the least characterized of the three PPAR subtypes. It is 
ubiquitously expressed, and is the most abundant subtype in skeletal muscle [85]. 
Furthermore, PPARį also shows a higher expression in oxidative type I fibers compared to 
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glycolytic type II fibers [86], while similar PPARį gene expressions were observed in non-
diabetic and diabetic muscle [87, 88]. PPARį signalling pathway plays a central role in 
regulation of skeletal muscle energy metabolism and especially in the adaptive responses to 
metabolic challenges, including sustained exercise training and during fasting [27, 65]. 
Endurance exercise and fasting both lead to increased FAs, and thereby activation of PPARį 
[82]. As also stated above, both fasting and sustained exercise are characterized by a shift 
from glucose to lipid utilization to cope with energy demand [89]. Expression of PPARį in 
skeletal muscle is also increased after exercise [90-92]. During fasting, the findings on 
PPARį expression has been inconsistent, varying from increased [93, 94] to decreased [95] 
expression.  
PPARį activation, either by FAs or the PPARį specific agonists GW501516 and GW0742, 
resulted in an increase in FA catabolism and promoted induction of several important genes 
involved in skeletal muscle lipid metabolism such as CD36, PLIN2, CPT1, angiopoietin-like 
protein 4 (ANGPTL4) and PDK4 [64, 85, 96-99]. Many of PPARį target genes are also 
induced by exercise, confirming the important role of PPAR mediating adaptive responses to 
exercise (discussed in more details under “Exercise and energy metabolism in skeletal 
muscle”, page 14). In skeletal muscle cells, GW501516 was also able to prevent palmitate-
induced inflammation and insulin resistance [100].While PPARį is a well-established 
regulator of lipid metabolism, the direct effect of PPARį activation on glucose utilization in 
skeletal muscle is conflicting, ranging from stimulation of glucose uptake and enhanced 
insulin-mediated effects [101, 102] to impaired glucose utilization [103]. In addition to be 
implicated in energy metabolism in skeletal muscles, PPARį is also involved in the 
regulation of lipid, lipoprotein and glucose metabolism in other tissues such as adipose 
tissue and heart [79]. 
Taken together, there is increasing evidence that PPARį is an important regulator of skeletal 
muscle energy metabolism, highlighting the potential utility of this isoform as a therapeutic 
option for treatment of metabolic disorders such as T2D. In fact, activation of PPARį by 
synthetic agonists is reported to ameliorate hyperglycemia, insulin resistance and 
dyslipidemia both in animals [98, 104] and humans [105-108]. 
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Exercise and energy metabolism in skeletal muscle 
An acute bout of exercise improves glucose homeostasis by increasing skeletal muscle 
glucose uptake, while regular exercise induces alterations in expression of metabolic genes 
such as those involved in mitochondrial activity, muscle fiber type or GLUT4 at protein 
levels [109]. The functional consequences of these adaptations are determined by duration, 
intensity, frequency and mode of exercise [110]. The ability to adapt and remodel in 
response to contractile activity in skeletal muscle allows the muscle to more efficiently 
utilize substrates for ATP production and thus become more resistant to fatigue [110, 111]. 
Endurance exercise-induced adaptations in energy metabolism are reflected as increases in 
mitochondrial content, both in size and number and improved lipid oxidative capacity [111-
113]. Regular exercise has also been shown to enhance both lipid synthesis and lipid 
oxidation [5, 114] and thereby resulting in an increase in IMTG [115]. As a consequence of 
these metabolic adaptations, trained skeletal muscle takes more of its required energy from 
lipids and less from glucose compared to untrained muscle during submaximal work [57, 
113, 116], and this is accounted for by an increase in IMTG utilization in the trained muscle 
[117, 118]. In skeletal muscle, HSL has previously been accepted to be the principal enzyme 
responsible for lipolysis of IMTG during exercise [119, 120], but recently, ATGL has 
emerged as the major player in lipolysis of IMTG during muscle contraction [47, 121]. 
Furthermore, enhanced FA oxidation after regular exercise is closely associated with the 
genes and proteins involved in regulating FA uptake across the plasma membrane (CD36) 
[122] and across the mitochondrial membrane (CPTI) [123, 124]. In addition, muscle 
contraction also promotes relocation of CD36 to both plasma membrane [125, 126] and the 
outer mitochondrial membrane [31, 127] thereby playing a role in FA uptake both into the 
cell and into the mitochondria (Figure 2). Moreover, several important mediators regulating 
mitochondrial activity and biogenesis are upregulated after regular exercise training, 
including PGC1Į [128, 129], cytochrome c [130, 131], and the TCA enzyme citrate synthase 
[132-134].  
In addition to enhanced FAs utilization, trained fibers import more glucose than untrained 
muscle fibers at resting state [135]. In the post-exercise period, the muscles display an 
increased sensitivity to insulin, resulting in increased glucose uptake and glycogen 
resynthesis [136-138]. It has been proposed that contraction stimulates GLUT4 translocation 
through a molecular mechanism different from that of insulin as muscle contraction has no 
15 
 
effect on the canonical insulin signaling pathways such as insulin receptor substrate (IRS) 
phosphorylation and PI3K activity [8, 111, 139]. In contrast, other studies have shown some 
degree of activation or phosphorylation of Akt in intact skeletal muscles in response to 
exercise [140, 141] and in situ muscle contraction [142, 143]. These discrepant findings 
suggest that contraction may regulate Akt in an intensity- and time-dependent manner. 
Although probably trough different mechanisms, signaling molecules involved in GLUT4 
translocation such as the Akt substrates TBC1D1 and TBC1D4 (AS160), are activated by 
both insulin and muscle contraction [144-147] (Figure 2).  
Contraction-induced molecular signaling is complex and involves a variety of signaling 
molecules including AMP-activated protein kinase (AMPK) and intracellular calcium. 
Muscle contraction leads to energy depletion (i.e. an elevated AMP/ATP ratio) and an 
increase in intracellular calcium that activates AMPK, which in turn increases glucose 
uptake and FA oxidation (Figure 2), suggesting that AMPK may be the primary mechanism 
mediating the adaptations to exercise (reviewed in [148]). However, data obtained from 
mouse models of attenuated AMPK activity demonstrated that inhibition of AMPK had little 
or no effect on contraction-induced glucose uptake [149], CD36 translocation to the plasma 
membrane and FA uptake [150] and mitochondrial marker (citrate synthase and succinate 
dehydrogenase) [109], indicating that additional signaling pathways are involved in 
triggering muscular adaptations. In addition to activate AMPK, prolonged influx of calcium 
into skeletal muscle during exercise activates calmodulin-dependent protein kinases (CaMK), 
which may also regulate glucose uptake independent of AMPK signaling [151]. Further, 
prolonged activation of CaMK in skeletal muscle also promote an increase in mitochondrial 
content [152]. 
Plasticity of skeletal muscle in response to regular exercise extends beyond the described 
metabolic changes. As also mentioned above, some of the key factors implicated in 
regulation of muscle fiber type and oxidative capacity are also known to be upregulated by 
exercise, including PPARį [91, 92], PGC1Į [128, 153] and MEF2 [154]. In endurance 
exercise, prolonged influx of FAs and long-term increase in intracellular calcium are shown 
to activate PPARį and MEF2, respectively (reviewed in [27]). Furthermore, MEF2 also 
induces PGC1Į [155] which in turn amplifies the activity of MEF2 and PPARį by acting as 
their coactivator, thus PGC1Į plays a central role in adaptation of skeletal muscle to exercise 
and is considered as a master transcriptional regulator of mitochondrial biogenesis and is 
also involved in increased GLUT4 expression [145, 153, 156-158]. Although the proportion 
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of oxidative type 1 fibers is reported to be increased after endurance exercise [69, 159, 160], 
it remains unclear whether regular exercise can switch type II fibers completely to type I 
fibers. Moreover, some of the known PPARį target genes, such as PDK4 [161] and 
ANGPTL4 [162] are also increased in the post-exercise period. Increase of ANGPTL4 by 
acute exercise is proposed to coordinate lipid uptake between exercising and non-exercising 
muscles [162]. Further, up-regulation of PPARį has been linked to improvements in clinical 
variables in diabetic subjects following exercise intervention. PPARį expression was 
unchanged in subjects who did not improve their clinical profile after exercise [91] 
suggesting a direct implication of PPARį in the muscle adaptations. Therefore, with all the 
evidence linking activation of PPARį to muscle performance, it is interesting to speculate 
whether pharmacological activators would enhance physical performance and even 
substitute for exercise. Indeed, administration of PPARį agonists to adult mice resulted in 
an increase in myofiber numbers [163] and increase in oxidative capacity [163, 164] and 
PPARį agonists are therefore proposed to act as exercise mimetics [165]. 
Physical activity plays an important role both in prevention and treatment of T2D [166-170], 
and as stated above, physical activity leads to major adaptations in skeletal muscle including 
altered gene expression and energy metabolism, but the individual contribution of these 
changes for improved physical health is unclear. It is important to remind that some 
exercise-mediated adaptations are reversible and thus the opposite effects are noted in 
response to inactivity [171].  
17 
 
 
Figure 2. Proposed signalling pathways for contraction-stimulated effects on metabolism in 
skeletal muscle. Contraction leads to energy depletion (i.e., an elevated AMP/ATP ratio) and 
elevated intracellular [Ca2+], which in turn leads to activation of AMP-activated protein kinase 
(AMPK) and calmodulin-dependent protein kinases (CaMK), respectively. Activated AMPK 
phosphorylates Akt substrate of 160 kDa (AS160, TBC1D4) and TBC1D1 at multiple 
phosphorylation sites and allows the conversion of less active GDP-loaded Rab to more active GTP-
loaded Rab. The more active GTP-loaded Rab then allows GLUT4 storage vesicles to move to and 
fuse with the plasma membrane. Translocation of GLUT4 is also mediated through the canonical 
insulin-signalling pathway via activating of insulin receptor substrates (IRS) and leading to 
phosphorylation of Akt. Contraction also promotes GLUT4, carnitine palmitoyltransferase (CPT1) 
and pyruvate dehydrogenase kinase isozyme 4 (PDK4) expressions. Activated AMPK and/or CaMK 
promote relocation of fatty acid (FA) transporter (CD36) to the plasma membrane and the outer 
mitochondrial membrane to increase FA uptake and oxidation. Contraction also leads to increase in 
lipolysis of lipid droplets by activating adipose triglyceride lipase (ATGL) and hormone-sensitive 
lipase (HSL). Prolonged influx of FAs and [Ca2+] also activate peroxisome proliferator-activated 
receptor į (PPARį) and myocyte enhancer factor 2 (MEF2), respectively, and thereby their target 
genes. AMPK and/or CaMK increase expression of peroxisome proliferator-activated receptor-Ȗ 
coactivator 1Į (PGC1Į) and nuclear respirator factor 1 (NRF-1), which then orchestrates the 
enhancement of mitochondrial biogenesis and function. Furthermore, PPARį, MEF2 and PGC1Į are 
all implicated in the oxidative fiber type program. Green arrows represent activation events, while 
yellow arrows represent processes probably not affected by contraction. 
18 
 
Skeletal muscle as a secretory organ 
Skeletal muscle has been identified as a secretory organ that releases a diversity of 
biologically active proteins classified as myokines that can have autocrine, paracrine or 
endocrine functions (reviewed in [172]). Muscle contraction during exercise is a major 
stimulus of these endocrine functions, and the myokines are thought to mediate beneficial 
effects of exercise and may have a role in the protection against conditions associated with 
low-grade inflammation, such as T2D, obesity and metabolic syndrome [173-175]. Both 
interleukin 6 (IL-6) and IL-8 are produced in contracting muscles and released into plasma 
during the post-exercise period [176-178] when the insulin sensitivity is enhanced [179]. It 
seems that IL-6 works as an energy sensor and preserve fuel availability during exercise 
[180] by enhancing insulin-stimulated glucose disposal and FA metabolism [181, 182], 
whereas IL-8 has been suggested to be involved in angiogenesis in skeletal muscle [183]. 
Interestingly, while IL-6 released from skeletal muscle may promote insulin sensitivity 
[184], IL-6 secreted from adipose tissue may induce insulin resistance in skeletal muscle 
[185]. In fact, plasma IL-6 is chronically elevated in obese [186, 187] and T2D subjects 
[188], and is positively correlated with insulin resistance [189]. In addition, chronic 
exposure of C2C12 cells to IL-6 has been shown to impair insulin-stimulated glucose uptake 
[190]. On the other hand, regular exercise can lower basal plasma levels of IL-6 [191]. Thus, 
while it has become evident that contracting skeletal muscle releases myokines that may 
influence metabolism and function of skeletal muscle and other tissues and organs, the 
secretion of myokines from obese and/or diabetic muscle is yet to be fully clarified.  
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Insulin resistance, obesity and type 2 diabetes 
The prevalence of T2D has increased worldwide during the last decades, and is projected to 
reach 592 million worldwide by the year 2035 [192]. It is established that a family history of 
T2D markedly increases the risk of the disease particularly in the first-degree relatives [193-
195], however, genome-wide association studies revealed only 10% of the estimated 
heritability of T2D can be explained [196]. Lifestyle factors such as obesity, physical 
inactivity, and consumption of a high-fat diet are all strongly involved in development of 
T2D [166, 167, 171, 197]. 
Overweight and obesity are usually defined either by body mass index (BMI), waist 
circumference or waist-hip-ratio. BMI  25 kg/m2 is considered overweight, BMI  30 
kg/m2 is considered obese, and BMI  40 kg/m2 is considered morbidly or severely obese 
[198]. In most cases, obesity is caused by an imbalance between energy intake and energy 
expenditure, although genetics and chronic stress are contributors [199-201]. More recently, 
evidence has emerged that the gut microbiota also influences metabolic processes and 
contribute to low-grade inflammation and obesity [202-205]. Majority of subjects with T2D 
are classified as overweight or obese [206]. Moreover, visceral adipose tissue increases the 
risk of T2D, while subcutaneous adipose tissue decreases the risk [207]. Mechanism behind 
the reported association between obesity and T2D are multifactorial, and may involve 
increased FA release from visceral adipose tissue and raised level of plasma FFAs [208] 
which contribute to excess lipid accumulation in liver and skeletal muscle [209, 210]. 
Furthermore, visceral adipose tissue is also prone to inflammation and inflammatory 
cytokine production contributing to a chronic low-grade inflammation [211]. It has become 
more evident that adipose tissue secretes numerous bioactive peptides, collectively called 
adipokines, which are proposed to play an important role in the adipose tissue-skeletal 
muscle crosstalk [210, 212-214]. However, obesity is preventable and onset of T2D can be 
delayed or prevented by lifestyle interventions such as healthy diet, regular physical activity, 
weight loss and pharmacological treatments [166-169].  
T2D is a metabolic disorder characterized by chronic hyperglycemia that affects the way the 
body utilizes energy. It is caused by a combination of factors, including defects in pancreatic 
ȕ-cells and insulin secretion and insulin resistance, a condition in which the body’s skeletal 
muscles, adipose and liver tissues do not respond effectively to insulin [215]. In skeletal 
muscle, insulin resistance is manifested as a decrease in glucose uptake and a decline in 
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muscle glycogen synthesis in response to insulin [209, 216]. In insulin-resistant subjects, the 
correlation between increased IMTG accumulation and insulin resistance has been firmly 
established [217-221]. Furthermore, decrease in IMTG storage after diet-induced weight loss 
is correlated with improvements in insulin sensitivity [222, 223]. However, despite the 
strong correlation of IMTG levels with insulin resistance, the exact mechanistic link 
between increased IMTG and reduced insulin sensitivity is unclear. The emerging idea is 
that increased IMTG turns to be deleterious when an increase in the supply of lipids to 
skeletal muscle is not balanced by an increase in the oxidative pathways, so that toxic 
intermediates, such as ceramides and DAG, accumulate in the cell and interfere with the 
insulin signaling [224, 225]. As the mitochondria are the main cellular sites devoted to FA 
oxidation, it has therefore proposed that impaired mitochondrial function leads to the 
accumulation of IMTG and lipid metabolites in skeletal muscles [195]. In fact, studies in 
humans have shown that T2D subjects exhibited alteration in mitochondrial morphology, as 
well as a decrease in the activity of the respiratory chain [226, 227]. Other studies showed a 
reduction in the expression of genes encoding key enzymes in oxidative mitochondrial 
metabolism such as PGC1Į in diabetic subjects [228]. As also mentioned above, cultured 
myotubes established from subjects with T2D, as well as those from obese subjects, have 
reduced capacity to oxidize FAs compared to cells from lean subjects [61, 62]. 
Mitochondrial function was also lower in T2D subjects than BMI-matched control subjects 
despite of similar IMTG content, suggesting that impaired mitochondrial function may be a 
more important determinant of diabetes than IMTG levels [229, 230]. However, other 
observations argue against the hypothesis that mitochondrial dysfunction underlies the 
development of T2D or IMTG accumulation as the IMTG accumulation may precede the 
development of mitochondrial dysfunction and/or that insulin resistance arises when 
mitochondrial function is unaffected or even improved [231, 232]. Therefore, it is not clear 
whether mitochondrial dysfunction represent a cause or a consequence of T2D. More 
recently, studies in rats have shown that an increase in phosphorylation efficiency in skeletal 
muscle mitochondria may promote accumulation of IMTG and contribute to the 
development of high-fat induced insulin resistance in skeletal muscle as less substrates are 
need to be burned to obtain the same amount of ATP [233, 234].  
Moreover, IMTG content is also reported to be similar in obese non-diabetic and obese 
diabetic subjects [235, 236]. Furthermore, in endurance-trained individuals, the IMTG 
content may be higher than in obese insulin-resistant subjects without affecting insulin 
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sensitivity or oxidative capacity, a phenomenon described as the athlete’s paradox [235, 237, 
238]. Similar to IMTG content in athletes, total muscle DAG content is also higher in 
athletes and correlated positively with insulin sensitivity [159]. Therefore, new theories to 
explain lipid-mediated muscular insulin resistance have emerged, which focus on abnormal 
lipid influx, storage, or TAG lipolysis and turnover rather than lipid storage per se [239]. 
Partitioning of more FAs toward TAG synthesis in skeletal muscle is correlated with 
increased insulin sensitivity [240], suggesting that a high expression levels of LD-associated 
proteins might be preferable. In fact, PLIN2 gene expression is lower in insulin-resistant 
obese subjects compared to obese controls [241], and higher PLIN2 protein content has been 
found in skeletal muscle of insulin-resistant subjects that have undergone weight loss or 
therapeutic treatments to increase muscle insulin sensitivity [242], suggesting that PLIN2 
might play a role in decreasing intramuscular lipid toxicity by promoting lipid storage. 
Moreover, improvements in insulin sensitivity following either endurance [115] or 
resistance training [243] are linked to increase in the content of PLIN2 and PLIN5. On the 
other hand, similar muscular PLIN2 protein content is observed between obese non-diabetics 
and obese diabetic subjects, and more interestingly, it correlated negatively with insulin-
stimulated glucose uptake [244]. Therefore, more insight into how PLIN2 regulates LD in 
skeletal muscle is needed. 
 
  
22 
 
AIMS OF PRESENT STUDIES 
The overall aim of this thesis was to study the regulation of energy metabolism in human 
skeletal muscle cells related to obesity and T2D, focusing on the metabolic effects of PPARį 
activation and in vitro exercise. To investigate the functional role of PLIN2 and LDs in 
skeletal muscle energy metabolism we also studied myotube cultures established from 
PLIN2+/+ and PLIN2-/- mice. More specifically, the objectives of the present studies were:  
 
1) To explore the effects of GW501516, a potent and selective PPARį agonist, on 
global gene regulation, FA and glucose utilization, as well as lipid distribution in 
myotubes from lean non-diabetic subjects (paper I). 
 
2) To investigate lipid accumulation, storage and turnover capacity, as well as oxidation 
and metabolic flexibility of myotubes from severely obese subjects with and without 
T2D (paper II). 
 
3) To explore glucose and lipid metabolism and gene expression after electrical pulse 
stimulation (EPS), as an in vitro model of exercise, as well as lipid metabolism 
combined with PPARį activation, in cultured myotubes established from lean non-
diabetic subjects and severely obese subjects (paper III). 
 
4) To explore lipid storage capacity and turnover, as well as lipid oxidation and glucose 
metabolism and muscle fiber type characteristics, in mice myotubes lacking PLIN2 
(paper IV). 
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SUMMARY OF PAPERS 
Paper I: PPARį activation in human myotubes increases mitochondrial fatty acid 
oxidative capacity and reduces glucose utilization by a switch in substrate preference  
The aim of this paper was to investigate the role of activation of peroxisome proliferator-
activated receptor į (PPARį) on global gene expression and mitochondrial fuel utilization in 
myotubes from lean non-diabetic subjects. PPARį is a well-established regulator of lipid 
metabolism in skeletal muscle, but effects on glucose utilization and fuel switching are less 
known. In addition, global gene analysis of PPARį activation in human myotubes had not 
previously been reported. 
Gene expression analysis using microarrays revealed that only 21 genes were significantly 
upregulated and 3 genes were significantly downregulated after 96 h of PPARį activation 
with the potent and selective agonist, GW501516. Genes such as PDK4, ANGPTL4, 
CPT1A, PLIN2 and CD36 were increased after PPARį activation. Pathway analysis showed 
upregulated mitochondrial FA oxidation, TCA-cycle and cholesterol biosynthesis. PPARį 
activation increased oleic acid oxidation and mitochondrial oxidative capacity by 2-fold. 
Glucose uptake and oxidation were reduced by 25%, while total substrate oxidation was 
unaffected, suggesting a fuel switch from glucose to FA. Cholesterol biosynthesis was 
increased by 30%, but lipid biosynthesis, the number of lipid droplets, lipolysis, 
mitochondrial content, and insulin sensitivity were unaffected. The effects of PPARį 
activation are summarized in Figure 3. 
In conclusion, this study confirmed that the principal effect of PPARį activation was to 
increase mitochondrial FA oxidative capacity. Moreover, results from the this study 
indicated that PPARį activation reduced glucose utilization through a switch in 
mitochondrial substrate preference by upregulating PDK4 and genes involved in lipid 
metabolism and FA oxidation. 
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Figure 3: Effects of PPARį activation in myotubes from lean non-diabetic subjects. Myotubes 
were treated for 96 h with 10 nM GW501516. Green arrows represent activation events, while red 
arrows represent inhibition processes. Yellow arrows indicate no effect of GW501516. 
Abbreviations: ANGPTL4, angiopoietin-like protein 4; ATGL, adipose triglyceride lipase; CD36, 
fatty acid transporter; CPT1A, carnitine palmitoyltransferase 1A; DAG, diacylglycerol; FA, fatty 
acid; FFA, free fatty acid; GLUT, glucose transporter; HSL, hormone-sensitive lipase; IRS, insulin 
receptor substrate; MAG, monoacylglycerol; PDK4, pyruvate dehydrogenase kinase isozyme 4; 
PLIN2, perilipin 2; PPARį, peroxisome proliferator-activated receptor subtype delta; TAG, 
triacylglycerol. 
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Paper II: Myotubes from severely obese type 2 diabetic subjects accumulate less lipids 
and show higher lipolytic rate than myotubes from severely obese non-diabetic subjects 
About 80% of patients with T2D are classified as overweight. However, only about 1/3 of 
severely obese subjects have T2D suggesting that several severely obese individuals may 
possess certain characteristics that protect them against developing T2D. Since skeletal 
muscle is the organ where insulin resistance is most pronounced, it was hypothesized that 
this apparent paradox could be related to fundamental differences in skeletal muscle lipid 
handling. Thus, the main focus of this study was to investigate lipid storage and turnover 
capacity, as well as oxidation and metabolic flexibility of myotubes from severely obese 
subjects (BMI  40 kg/m2) with and without T2D.  
Lower insulin sensitivity was observed in myotubes from severely obese subjects with T2D 
confirming that myotubes maintain their diabetic phenotype in culture. Lipolysis rate was 
higher, and oleic acid accumulation, TAG content, and FA adaptability were lower in 
myotubes from severely obese subjects with T2D compared to severely obese non-diabetic 
subjects. There were no differences in lipid distribution and mRNA and protein expression 
of the lipases HSL and ATGL, the lipase cofactor CGI-58, or the LD-associated proteins 
PLIN2 and PLIN3. In addition, glucose and FA oxidation, and the expression of oxidative 
phosphorylation (OXPHOS) proteins were also similar in cells from the two donor groups 
despite of lower mitochondrial staining. The findings in myotubes from severely obese 
diabetic subjects are summarized in Figure 4. 
Thus, lower lipid accumulation and higher lipolysis without correspondingly increased FA 
oxidation and impaired metabolic flexibility, as observed in T2D myotubes, could contribute 
to accumulation of lipotoxic intermediates, which can interfere with insulin signalling. In 
conclusion, difference in intramyocellular lipid turnover might be fundamental in evolving 
T2D.  
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Figure 4: Energy metabolism and metabolic flexibility in myotubes from severely obese 
diabetic subjects when compared to myotubes from non-diabetics with similar BMI. Green 
arrows represent a higher event in diabetic than in non-diabetic myotubes, while red arrows represent 
a lower process. Yellow arrows indicate no differences between diabetic and non-diabetic myotubes. 
Adaptability is the ability to increase fatty acid oxidation with increasing fatty acid concentration. 
Abbreviations: ATGL, adipose triglyceride lipase; CD36, fatty acid transporter; CPT1B, carnitine 
palmitoyltransferase 1B; CYC1, cytochrome C-1; DAG, diacylglycerol; FA, fatty acid; FFA, free 
fatty acid; GLUT, glucose transporter; HSL, hormone-sensitive lipase; MAG, monoacylglycerol; 
MYH7, myosin heavy chain 7 (the gene that regulates protein expression enriched in type I fibers); 
PDK4, pyruvate dehydrogenase kinase isozyme 4; PGC1Į, peroxisome proliferator-activated 
receptor gamma coactivator-1Į; PI3-kinase, phosphatidylinositol 3-kinase; PLIN2/3, perilipin 2/3; 
TAG, triacylglycerol.   
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Paper III: Myotubes from lean and severely obese subjects with and without type 2 
diabetes respond differently to an in vitro model of exercise 
Exercise improves insulin sensitivity and oxidative capacity in skeletal muscles. However, 
the effect of exercise on substrate oxidation is less clear in obese and T2D subjects than in 
lean subjects. In this paper, we used an in vitro model of exercise (EPS) to explore whether 
there were differences in EPS response on insulin sensitivity, glucose and lipid metabolism 
and gene expression in cultured myotubes established from lean non-diabetic subjects and 
severely obese subjects (BMI  40 kg/m2) with and without T2D. Moreover, we explored 
the combined effect of EPS together with GW501516, on lipid metabolism as well. 
We observed an EPS-induced increase in insulin sensitivity, but no improvement in lipid 
oxidation in myotubes from severely obese subjects. Thus, the EPS-induced increases in 
insulin sensitivity and lipid oxidation were positively and negatively correlated to BMI of 
the subjects, respectively. Further, EPS enhanced oxidative capacity of glucose in myotubes 
from all subjects, while mitochondrial content were only increased in myotubes from lean 
subjects. FA oxidation was increased after GW501516 treatment in myotubes from all 
subjects, whereas combination of GW501516 treatment and EPS showed no additional 
effect on FA oxidation. Furthermore, EPS reduced mRNA expression of oxidative fiber-type 
marker (MYH7) in myotubes from diabetic subjects; however the protein expression of this 
marker was not significantly affected by EPS in neither of the donor groups. On the contrary, 
mRNA levels of IL-6 and IL-8 were unaffected by EPS in myotubes from diabetic subjects, 
while IL-6 mRNA expression was increased in myotubes from non-diabetic subjects. EPS-
stimulated mRNA expression levels of MYH7, IL-6 and IL-8 correlated negatively with the 
subjects’ HbA1c and/or fasting plasma glucose, suggesting an effect linked to the diabetic 
phenotype. The effects after EPS or PPARį activation are summarized in Table 1. 
In conclusion, these data indicate that myotubes from various donor groups respond 
differently to EPS, and this effect also reflect the in vivo characteristics of the donor groups, 
suggesting that some individuals may inherently respond differently to exercise. Results 
suggest that pharmacological activation of PPARį could be one way to increase FA 
oxidation in subjects that seem to be unresponsive to exercise-mediated effect on FA 
metabolism.  
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Table 1: Effects of EPS for 48 h or PPARį activation for 96 h in myotubes established from 
lean, non-diabetics and severely obese subjects with and without type 2 diabetes (T2D). An 
increase or a decrease after treatment with either EPS or PPARį activation is indicated with Ĺ and Ļ, 
respectively. (-) indicates no effect of EPS. Lipid oxidation and uptake were not further increased 
with PPARį activation and EPS in combination. Abbreviations: EPS, electrical pulse stimulation; 
MYH7, myosin heavy chain 7 (the gene that regulates protein expression enriched in type I fibers) 
pAkt/Akt, phosphorylation of Akt/total Akt. 
After EPS Lean non-diabetic Obese non-diabetic Obese diabetic 
pAkt/Akt - - - 
Glycogen synthesis  - - - 
Insulin sensitivity - ј ј 
Glucose oxidation ј ј ј 
Lipid oxidation ј - - 
Mitochondrial content ј - - 
Lipid droplet number - - - 
Neutral lipid content - - - 
Lipid uptake - - - 
MYH7 (gene) - - љ 
Interleukin-6 (gene) ј ј - 
After PPARį activation    
Lipid oxidation ј ј ј 
Lipid uptake ј ј ј 
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Paper IV: A metabolic shift in energy metabolism from utilization of glucose towards 
fatty acids in myotubes lacking perilipin 2 
LD-associated proteins are essential for the formation and stability of intracellular LDs. 
However, the roles of PLIN2, which is an abundant LD-associated protein in skeletal muscle, 
remain unclear. In this paper, by using cultured myotubes established from PLIN2+/+ and 
PLIN2-/- mice we aimed to investigate the functional role of PLIN2 on lipid storage and 
turnover capacity, as well as on lipid oxidation and glucose metabolism. We further 
explored the role of PLIN2 on insulin-stimulated responses and muscle fiber type 
characteristics. 
We observed reduced number of LDs, reduced incorporation of labeled oleic acid (OA) into 
TAG and DAG and increased TAG hydrolysis in PLIN2-/- myotubes. Absence of PLIN2 
resulted in a metabolic shift in energy metabolism from utilization of glucose towards FAs. 
Accordingly, myotubes established from PLIN2-/- mice had higher OA oxidation and lower 
glycogen synthesis and glucose oxidation compared to PLIN2+/+ cells. Ablation of PLIN2 
also resulted in higher gene expressions of PDK4, a key enzyme important for switching 
fuel source from glucose to FA, PGC1Į, known to stimulate expression of genes important 
for FA oxidation. We also found that loss of PLIN2 resulted in higher gene expression of the 
oxidative fiber type marker (MYH7) and lower expressions of the glycolytic fiber type 
markers (MYH1, -2 and -4). However, loss of PLIN2 had no impact on insulin-stimulated 
responses. Energy metabolism and lipid turnover in PLIN2-/- myotubes are summarized in 
Figure 5. 
In conclusion, these results suggest that PLIN2 is essential for balancing the pool of skeletal 
muscle LDs to avoid an uncontrolled hydrolysis of the intracellular TAG pools and the 
metabolic consequences of an increased release of FAs from LDs.  
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Figure 5: Energy metabolism and lipid turnover in myotubes lacking perilipin 2 (PLIN2-/-) 
when compared to myotubes with a functional perilipin 2 (PLIN2+/+). Green arrows represent a 
higher event in PLIN2-/- than PLIN2+/+ myotubes, while red arrows represent a lower process. 
Yellow arrows indicate no differences between PLIN2-/- myotubes and PLIN2+/+ myotubes. 
Abbreviations: ATGL, adipose triglyceride lipase; CPT1B, carnitine palmitoyltransferase 1B; DAG, 
diacylglycerol; FA, fatty acid; FFA, free fatty acid; GLUT, glucose transporter; HSL, hormone-
sensitive lipase; IRS, insulin receptor substrate; MAG, monoacylglycerol; MEF2c, myocyte 
enhancer factor 2c; MYF5, myogenic factor 5; MYH, myosin heavy chain; MYOD1, myogenic 
differentiation protein 1; PDK4, pyruvate dehydrogenase kinase isozyme 4; PGC1Į, peroxisome 
proliferator-activated receptor gamma coactivator-1Į; PPAR, peroxisome proliferator-activated 
receptor; TAG, triacylglycerol.  
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METHODOLOGICAL CONSIDERATIONS 
Cultured skeletal muscle cells as an in vitro model 
Cultured human myotubes represent an in vitro model system for intact skeletal muscle, and 
have the most relevant genetic background for study of metabolic pathways and processes in 
human skeletal muscle (as opposed to rodent cell cultures) [245]. Moreover, human 
myotubes used here are not immortalized which allows investigation of the innate 
characteristic of the donors they were established from. Extracellular environment can be 
precisely monitored, thus making this system possible to study cellular mechanism and 
underlying signaling pathways under controlled conditions.  
The human muscle cells used in this thesis were obtained from biopsies from M. obliquus 
internus abdominis. The lean non-diabetic donor biopsies were obtained from subjects 
donating a kidney at Oslo University Hospital, Norway (papers I and III) and the severely 
obese donor biopsies were obtained from subjects undergoing bariatric surgery at The 
Morbid Obesity Center, Vestfold Hospital Trust, Norway (papers II and III). The isolation 
of satellite cells from all biopsies was performed at the same location and by the same 
researchers. To be able to study the role of PLIN2 in skeletal muscle, muscle myoblast 
cultures were established from the hind leg containing M. gastrocnemius and M. soleus from 
PLIN2+/+ and PLIN2-/- mice (paper IV). We disrupted the PLIN2 gene using standard 
homologous recombination in embryonic stem cells. The use of knockout mice enables us to 
study the role of one specific protein at a time; however, silencing of a gene may elicit 
compensatory cellular responses through up-regulation of genes sharing overlapping 
functions. However, as we showed in paper IV, complete loss of PLIN2 was not 
compensated by other related PLIN genes. Full knockout of the gene is superior compared to 
silencing with siRNA, as some expression of the target gene will be retained after silencing 
with siRNA. In comparing metabolic studies between different species, it is important to 
consider the differences existing between the species with regard to metabolic regulation 
(reviewed in [246]). For example, mouse has a basal metabolic rate that is ׽7.5-fold greater 
than that of the human. Furthermore, it appears that glucose tolerance in mice is more 
closely related to hepatic rather than skeletal muscle insulin action.  
Cultured human myotubes are generally characterized by low mitochondrial capacity and 
their fuel preference for carbohydrate over lipids [245]. The GLUT1:GLUT4 ratio is higher 
in cultured myotubes compared to adult skeletal muscle [247-249] resulting in lower insulin 
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responsiveness on glucose transport. Typically, insulin increases glucose uptake by 40-50 % 
in myotubes [247, 250]. However, despite the reduced insulin-responsiveness, the 
mechanisms involved in glucose uptake in vivo are conserved in vitro [247].  
Mature human myotubes do not typically contract spontaneously [250], and to overcome 
this limitation, myotubes were stimulated with electrical pulses. As shown in paper III and 
also reported by others [251, 252], EPS can induce responses in cultured myotubes that are 
similar to those observed in exercising muscle in vivo, making this model important for 
clarifying the mechanisms for contraction-stimulated glucose uptake and exercise-induced 
adaptations in cellular energy metabolism. 
Another aspect to consider when comparing myotubes obtained from different sources of 
muscle satellite cells is heterogeneity with respect to muscle fiber types. However, studies 
have shown that human satellite cells isolated from either fast or slow muscle fibers form 
myotubes in vitro which co-express both fast and slow fibers independently of the fiber type 
from which they originated [253]. Further, it has been reported that myotubes express fast 
fiber type regardless of donor muscles having mixed fiber type expression in vivo [254]. 
Furthermore, murine satellite cells isolated from various muscles are uniform regardless of 
muscle origin and the dominant muscle fiber type is the intermediate fiber type, MHCIIa 
[255]. In our cells, after 8 days of differentiation, we observed a significant amount of slow 
fiber type as well [245]. Taken together, these findings demonstrate that myotubes differ 
from donor muscle with respect to MHC expression. However, we have previously shown 
that cell content of MHCI is increased in electrically pulse stimulated myotubes [252], 
showing a plasticity potential of these cells.  
Several characteristics of the in vivo phenotype are conserved in culture. For instance, the 
diabetic phenotype is conserved in myotubes [256, 257]. The ability of the skeletal muscle 
to switch between lipid and glucose oxidation appears to be an intrinsic characteristic, as it 
was retained in vitro [63, 258]. Further, altered lipid metabolism in skeletal muscle with 
diabetes and obesity [61, 62] is also retained in culture. The precise mechanisms by which 
myotubes are able to retain the in vivo characteristics are not known. However, a 
combination of genetic and epigenetic mechanisms are probably involved, and this has been 
reviewed in a recent paper [245]. For example, epigenetic regulation of skeletal muscle stem 
cells and skeletal muscle differentiation, exercise, diet and a family history of T2D have all 
been described to influence DNA methylation and/or histone modifications in human 
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skeletal muscle [90, 259], and these are traits that might follow the isolated satellite cells 
into their corresponding cultured myotubes. 
Although the diabetic phenotype is stable in an uniform culture environment [260], it has 
also been shown that the ability of the myoblast to fuse and differentiate into myotubes and 
metabolic processes such as glucose uptake, glycogen synthesis, glucose and FA oxidation 
can gradually become impaired with increasing passage number [261]. For that reason, all 
the experiments performed in this thesis were on cells from passage numbers that exerted 
normal responses. Taken together, although some limitations, the cell model used in this 
thesis appears to be valuable to study skeletal muscle metabolism including conditions such 
as T2D, insulin resistance, obesity and EPS-induced responses.  
 
Donor characteristics  
Cultured myotubes used in the thesis were established from biopsies from adult donors of 
different ages (26-70 years). Both genders are included, although the majority of the donors 
were women (64%). The average age of the donors was 46 years. The lean non-diabetic 
donors used in the thesis had an average BMI of 24 kg/m2, while the severely obese donors 
had average BMI of 43 kg/m2, with lower HDL and higher TAG levels than the lean non-
diabetic donors. Fasting plasma glucose and HbA1c were higher in severely obese donors 
with T2D than in non-diabetic donors (Table 2). In addition to T2D, the donors may also 
possess other diseases or conditions such as hypertension.  
Table 2: Donor characteristics for the three donor groups used in the thesis: lean non-diabetic 
(L-nD, n = 20), severely obese non-diabetic (SO-nD, n = 16) and severely obese with type 2 diabetes 
(SO-T2D, n = 14). Mean values are presented. HbA1c and plasma insulin were not measured in the 
lean non-diabetic cohort. *Significantly different from L-nD. †Significantly different from the non-
diabetic groups. #Significantly different from SO-nD. P < 0.05, two-tailed unpaired Student’s t-test 
was used to compare two groups, whereas ANOVA with Bonferroni adjustment was used for 
multiple comparisons. BMI; body mass index, HbA1c; glycosylated hemoglobin, HDL; high-density 
lipoprotein, LDL; low-density lipoprotein, TAG; triacylglycerol. 
 Age BMI  Fasting glucose HbA1c  Insulin HDL TAG 
Total 
cholesterol 
 years (kg/m2) (mM) (%) (pM) (mM) (mM) (mM) 
L-nD 48 24 5.4 - - 1.5 1.0 5.1 
SO-nD 41 44* 5.0 5.4 96 1.2* 1.6* 4.8 
SO-T2D 49 41* 7.9† 7.1# 82 1.1* 2.0* 4.5 
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BMI as a measure of obesity is widely used because of its simplicity and validation in 
multiple epidemiologic studies. The main limitation of BMI is that it cannot differentiate 
body fat from lean mass and central (visceral) fat from peripheral (subcutaneous) fat. 
Therefore, athletes with enhanced body muscle mass may be misclassified as obese when 
using only BMI to diagnose obesity, whereas individuals with low lean body mass but high 
body fat content may still have a normal BMI. Furthermore, individuals with normal BMI ( 
25 kg/m2) and high body fat percentage also show a high degree of metabolic dysregulation 
(normal weight obesity) [198].  
Gender is definitely a factor affecting energy metabolism in vivo as women are more insulin 
sensitive than men, despite higher IMTG levels [262-264], higher adipose mass and less 
skeletal muscle mass [265] compared to men. In addition, women have been reported to 
have higher expression of FA transport proteins [266], higher lipid turnover such as 
increased esterification of FAs and lipolytic activity [267, 268] and higher level of muscle 
fiber type 1 [68, 262] than men, while men have higher whole-body resting energy 
expenditure [269] than women. However, these differences do not seem to be maintained in 
cultured myotubes, as both glucose and palmitic acid metabolism were similar in myotubes 
from male and female donors [270, 271] indicating the importance of influence from sex 
hormones and other factors in vivo. Similarly, gene expression of several genes involved in 
glucose and lipid metabolism that been observed to be higher in muscle biopsies from 
females than men, the gene expression was similar in cultured myotubes from the same 
donors [270, 271]. In addition, the expression patterns of fiber type markers seem to be the 
same in myotubes from female or male donors [253]. Thus, in the studies included in this 
thesis, data obtained from donors of both genders were merged.  
In vivo, age affects several metabolic processes in skeletal muscles such as impaired insulin 
sensitivity and increased obesity with increasing age [272-274]. Increasing age has also been 
associated with elevated decline in skeletal muscle mass [275] and increased proportions of 
fast muscle fibers [276], oxidative damaged to mitochondrial DNA [277-279], reduced 
mitochondrial content [280, 281] and function [272]. Additionally, the PPARį content of 
skeletal muscles has been reported to decline with increasing age [282], whereas IMTG 
content increased with advancing age [281]. However, obesity and inactivity rather than age 
per se are suggested to be more important in age-related declines in insulin sensitivity [273]. 
Moreover, several of these age-related effects may be prevented by exercise [274, 283], and 
the ability to adapt to exercise with an increase in muscle mitochondria is maintained up to 
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at least 70 years [284, 285]. In this thesis, the majority of the donors used were under the age 
of 60 years, and experimental data from donors of all ages were merged. 
 
Methods used to measure energy metabolism in cultured skeletal muscle cells  
Metabolic processes in the thesis were described by combining functional studies using 
radiolabeled substrates with gene expression analysis using both real-time qPCR and 
microarray, as well as staining of LDs and mitochondria followed by live cell imaging. In 
this thesis, scintillation proximity assay (SPA) was used to study both real-time substrate 
accumulation and lipolysis. After 24 h of accumulation of radiolabeled oleic acid (OA), SPA 
was performed without OA present in the media where efflux of accumulated OA 
represented a measure of lipolysis. In addition, the radioactivity released to the culture 
media was also measured. The substrate oxidation assay [286] was used to study oxidation 
and metabolic flexibility. Microarray (used in paper I) is a valuable screening tool for gene 
expression, generating great amount of data, although relatively high costs and risk of false 
positive findings being the main drawbacks of this method. On the other hand, real-time 
qPCR is useful for investigation of a limited number of anticipated regulated genes and gene 
set enrichment analysis with focus on groups of genes that share common biological 
function, chromosomal location, or regulation [287]. Immunoblotting was also applied to 
assess the expression and phosphorylation of relevant proteins, thereby addressing changes 
in post-translational modifications. However, immunoblotting is highly dependent on the 
quality of the antibodies that are used, and is therefore a semi-quantitative method. Staining 
of LDs and mitochondria followed by live imaging is another method that was used in order 
to get a broader understanding of the cellular changes. The cells were incubated with 
fluorescent substances that are known to diffuse through the plasma membrane and bind to 
intracellular organelles. After excitation of the fluorophore, the emitted light can be 
quantified. In this thesis, muscle cells were labeled with Hoechst 33258, MitoTracker®Red 
FM and Bodipy 493/503. Hoechst 33258 binds to double stranded DNA and Bodipy 
493/503 is a lipophilic dye that accumulates in non-polar neutral lipids and is rather specific 
for LDs [288]. The image acquisition and analysis was automated and the images were taken 
randomly, avoiding the potential bias from the operator. MitoTracker®Red FM is a 
fluorescent dye containing a mildly thiol chloromethyl moiety that accumulates within 
active mitochondria. However, there are some controversies regarding the MitoTracker®Red 
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FM dye’s limitation as a specific marker, for instance its dependence on membrane potential 
and oxidative capacity [289], and that interpretations should be carried out with caution. In 
our lab, we have observed increased staining of MitoTracker®Red FM in parallel with 
higher OA oxidation [252], while we have also observed that MitoTracker®Red FM was 
unchanged despite increased oxidation [64, 290] as well also shown in paper I. Further, we 
have also treated cells with a mitochondrial uncoupler (FCCP), without effect on 
MitoTracker®Red FM staining (unpublished data). In support of our conclusion regarding 
use of MitoTracker®Red FM, we and others have shown that citrate synthase activity, which 
is another measure of mitochondrial content, had similar pattern as MitoTracker®Red FM in 
human myotubes [252, 291]. Thus, this dye seems to stain mitochondria independently of 
oxidative status in myotubes and therefore possibly independently of membrane potential, 
implying that, limited to these cells and our conditions, it is a good measure of 
mitochondrial content. More importantly, mitochondrial content should be assessed in more 
than one way, such as shown in paper II and III where we combined MitoTracker®Red FM 
staining with measuring expression levels of proteins involved in mitochondrial oxidative 
phosphorylation (OXPHOS). 
In the present thesis, several approaches were applied to explore energy metabolism in 
cultured skeletal muscle cells. In paper I, pharmacological activation of PPARį with a 
selective and highly potent agonist, GW501516, was used to explore mitochondrial fuel 
utilization in myotubes. We have previously established an in vitro model of regular exercise 
of human myotubes by applying chronic, low-frequency electrical pulse stimulation (EPS, 
single, bipolar pulses of 2 ms, 30 V, 1 Hz continuously for 48 h) [252]. In paper III, we 
used this in vitro exercise model to explore EPS responses in myotubes from different donor 
groups. Further, we also explored the combined effect of EPS together with GW501516 on 
lipid metabolism.  
Various compounds (research tools) were used to modify lipid turnover from the IMTG pool 
in myotubes, such as an inhibitor of ACSL (triacsin C) [292], an inhibitor of HSL 
(CAY10499) [293] and an inhibitor of AGTL (Atglistatin) [294]. TAG resynthesis [45] and 
FA oxidation [290] are efficiently blocked by triacsin C, while lipolysis is increased [290]. 
Re-esterification was calculated as [triacsin C present - triacsin C absent] as previously 
described [290, 295, 296]. 
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DISCUSSION AND CONCLUSIONS 
In the present thesis, energy metabolism was investigated in cultured skeletal muscle cells 
established from different donor groups (lean non-diabetic, severely obese non-diabetic and 
severely obese type 2 diabetic) and mice (PLIN2+/+ and PLIN2-/-). In paper I, GW501516 
was used to explore the effect of PPARį activation on global gene expression and 
mitochondrial fuel utilization in myotubes from lean non-diabetic donors. In paper II, we 
explored differences in the metabolic processes in myotubes derived from severely obese 
subjects with and without T2D, whereas in paper III we investigated the effect of exercise-
mimicking treatment by using EPS alone, or in combination with GW501516 on human 
myotubes from all three donor groups. Finally, in paper IV we investigated the functional 
role of PLIN2 on lipid turnover and energy metabolism as well as muscle fiber remodelling 
in myotubes from mice. 
 
Oxidative capacity and metabolic flexibility 
Cultured human myotubes are characterized by their low mitochondrial oxidative potential. 
Three of the papers (I, III, IV) presented in this thesis showed increased mitochondrial 
oxidative capacity for lipids, by using different experimental approaches. Impairments have 
been noted in skeletal muscle glucose and FA oxidation in obesity and T2D in the resting 
state [57, 62, 297]. It is therefore important to determine whether interventions, either 
exercise or pharmacological, can effectively reverse these impairments.  
In skeletal muscle, PPARį mRNA is expressed to a greater extent than PPARĮ, while 
PPARȖ mRNA level is very low [65] as we also observed in cultured mice myotubes (paper 
IV). In paper I, we showed for the first time global gene analysis and gene set enrichment 
analysis of PPARį activation in human myotubes from lean non-diabetic donors. Activation 
of PPARį with GW501516 resulted in a robust activation of some essential genes involved 
in lipid metabolism and FA oxidation. In line with this, pathway analysis showed 
upregulated mitochondrial FA oxidation and TCA-cycle. Further, mitochondrial FA 
oxidative capacity of lipids was increased after PPARį activation (papers I and III) in 
human myotubes from all donor groups, while lipid oxidation after EPS stimulation was 
only increased in myotubes from lean non-diabetic donors (paper III). Furthermore, uptake 
of FA was also increased after PPARį activation in human myotubes from all donor groups 
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(papers I and III), but not in EPS-stimulated cells from neither lean nor obese donors 
(paper III). Although only shown in myotubes from lean non-diabetic donors, the increase 
in FA uptake and oxidation after PPARį activation were accompanied by enhanced gene 
expressions of CD36 and CPT1A (paper I) without affecting mitochondrial content.  
PPARį agonist and exercise training are proposed to synergistically increase oxidative 
myofibers in adult mice [164]. However, factors important for FA oxidation such as CPT1B 
and PDK4 were not further induced with exercise compared to PPARį activation alone 
[164], which is consistent with the findings that FA oxidation was not further increased 
when combining PPARį activation and EPS (paper III). In comparison, mitochondrial 
content was increased after EPS-treatment (paper III) in lean non-diabetic donors, while it 
remained unchanged after PPARį activation (paper I). This is in concordance with a 
previous report, which found that PPARį increased FA oxidation without affecting 
mitochondrial gene expression and function [298]. In addition, neither mitochondrial 
biogenesis nor PGC1Į have been shown to be increased after pharmacological activation of 
PPARį [92, 101, 299-301]. Although it has been shown that exercise increase both 
mitochondrial content and intrinsic mitochondrial function in obese and insulin-resistant 
subjects [302], it has also been reported that exercise did not change key regulators of 
mitochondrial biogenesis in skeletal muscles in diabetic men after exercise [303]. Consistent 
with this, in our exercise model, myotubes from donors with higher BMI were less 
responsive to exercise-induced effects on FA oxidation and mitochondrial content than 
myotubes from lean donors (paper III). In contrast, increase in muscle ex vivo palmitic acid 
oxidation in obese subjects has been observed after in vivo exercise [304]. The discrepancy 
may to some extent be explained by differences between in vivo and in vitro exercise 
models. Without EPS, there was no difference in basal lipid content between myotubes in 
the three donor groups (paper III), excluding the possibility that the absence of EPS effect 
on FA oxidation is due to label dilution when using a labelled FA as a measurement of FA 
oxidation.  
Taken together, after PPARį activation, increased FA oxidation may partly due to an 
increase in FA uptake via CD36, an increase in flux of long-chain FAs across the 
mitochondrial membrane via CPT1A, and by switching the oxidation from glucose towards 
FA (paper I) without affecting mitochondrial content, while the EPS-induced effect on FA 
oxidation may due to an increase in mitochondrial content (paper III). Additionally, with no 
effect on FA oxidation after EPS, but increased FA oxidation after PPARį activation (paper 
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III) in myotubes from obese donors may suggest that pharmacological activation of PPARį 
could be one way to increase FA oxidation in subjects that seem to be unresponsive to 
exercise-mediated effect on FA metabolism.  
Both glucose uptake and oxidation were decreased after PPARį activation in human 
myotubes from all donor groups (paper I and Figure 6 (unpublished data)), while glucose 
uptake assessed as glycogen synthesis remained unchanged after EPS stimulation (paper 
III).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6: PPARį activation reduced glucose oxidation and uptake. Myotubes established from 
severely obese non-diabetics (SO-nD) and severely obese type 2 diabetics (SO-T2D) were treated for 
96 h with 10 nM GW501516 or 0.1% vehicle (DMSO). Glucose oxidation and uptake were 
measured in presence of [14C]glucose (0.5 ȝCi/ml, 200 M) for 4 h. Glucose uptake was assessed as 
the sum of oxidized glucose (trapped CO2) and remaining cell-associated radioactivity (accumulated 
[14C]glucose). Data are presented as mean ± SEM (n=5-7). *P ޒ 0.05 versus DMSO. 
 
Like PPARį activation, ablation of PLIN2 also resulted in a metabolic shift in energy 
metabolism from utilization of glucose towards FAs (paper IV). Accordingly, a higher FA 
oxidation and lower glucose metabolism was observed in PLIN2-/- myotubes. In addition, 
transcription factors such as PPARĮ and PGC1Į, known to facilitate FA oxidation [157, 305] 
were also higher expressed in PLIN2-/- myotubes, whereas PPARȖ, which stimulates 
expression of genes promoting lipid storage [79], were lower (paper IV). Similar 
differences in PPARĮ expression have been observed in livers of PLIN2+/+ and PLIN2-/- 
mice [306] whereas the oposite expression pattern is found in muscle electrophorated to 
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overexpress PLIN2 [307]. As stated above, PDC is positioned in such way that it plays one 
of the most central roles in regulation of glucose metabolism as well as fuel selection in 
skeletal muscle [54]. In fact, both PPARį activation (paper I) and ablation of PLIN2 (paper 
IV) resulted in an increase in PDK4 expression. As PDK4 is known to inhibit PDC [54] and 
thereby reduces glucose oxidation, we confirmed in paper I and IV that PDK4 is an 
important enzyme for switching the fuel source from glucose to FA. In support, others have 
also shown that PDK4 is increased after PPARį activation [96, 98, 102, 308]. Furthermore, 
PDK4 inhibition of glucose oxidation in response to elevated plasma FA availability has 
been observed during fasting [309, 310] or high-fat feeding [311]. Under these conditions, 
carbohydrate availability is low, so PDK4 contributes to glucose sparing by preventing its 
oxidation. Therefore, by regulating PDK4, PPARį is suggested to play a role in utilization 
of FAs under physiological conditions. On the other hand, trained muscle fibers have been 
shown to use more glucose than untrained fibers [135, 312] with enhanced carbohydrate 
oxidation after exercise in obese subjects [313], and in subjects with T2D [314]. Consistent 
with this, we showed that EPS was able to increase oxidative capacity of glucose in human 
myotubes from all donor groups (paper III).  
Adaptability of FA metabolism is shown to correlate positively with insulin sensitivity [63], 
and lower ability to increase FA oxidation with increasing FA concentration is observed in 
myotubes from obese type 2 diabetics [315]. In accordance, as we showed in paper II, 
obese diabetic myotubes had lower ability to increase FA oxidation with increased FA 
availability (i.e. lower adaptability). Additionally, reduced metabolic flexibility is also 
shown in vivo in insulin resistant muscle [60] implying that impairment in diabetic muscle 
mitochondria to exchange substrate in demand. In addition, we found lower mitochondrial 
staining in myotubes from obese donors with T2D compared to cells from obese non-
diabetic donors, which is consistent with earlier study showing lower mitochondrial content 
in insulin resistant muscle [316]. This occurred despite no differences in FA and glucose 
oxidation between lean and obese myotubes (paper III) or differences in the OXPHOS 
protein expression or mRNA expression of CYC1, PGC1Į CPT1B or PDK4 between the 
obese non-diabetic and obese diabetic myotubes (paper II). Although, FA oxidation at 
resting state is shown to be reduced in obese versus lean muscle [59, 62, 297, 317], other 
studies have also reported similar FA oxidation between myotubes from lean and obese 
diabetic subjects [236] and even increased oxidation in obese muscle compared to lean 
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[231]. The reason behind this discrepancy is unclear, but may be a result of different 
subgroups of obese populations studied and/or different methodology used. 
 
Fast-to-slow transformations in skeletal muscles 
An association between insulin sensitivity and the amount of oxidative type I fibers has been 
suggested, as a lower expression of type I fibers has been demonstrated in muscle biopsies 
from insulin resistant and T2D subjects when compared to healthy subjects [74, 318]. On the 
other hand, no differences in fiber type compositions were found between muscle biopsies 
from lean non-diabetic and obese diabetic subjects [316]. Furthermore, as discussed above, 
myotubes in culture differ from donor muscle as human satellite cells form myotubes in 
vitro independently of the fiber type from which they originated. Consistent with this, we 
showed in paper II and III that there was no difference in expression level of muscle fiber 
type I marker between the myotubes from lean non-diabetic and obese subjects (paper III), 
or between the myotubes from obese non-diabetic and diabetic subjects (papers II and III). 
After EPS, we observed reduced mRNA expression of muscle fiber type I marker (MYH7) 
in myotubes from diabetic subjects; however the protein expression of this marker was not 
significantly affected by EPS in neither the lean nor obese donor groups (paper III). We 
showed in paper III that metabolic adaptations such as EPS-induced increase in oxidative 
capacity and mitochondrial content can occur irrespective of an altered muscle fiber marker 
expression profile. Although the possibility of conversion from type II to type I muscle 
phenotype in adult humans has been debated [319, 320], this type of transition has been 
consistently shown in rodent with different approaches [78, 86, 92, 321, 322]. In paper IV, 
ablation of PLIN2 in mice resulted in myotubes that were more oxidative and less 
glycolytic. Furthermore, loss of PLIN2 resulted also in a higher gene expression of oxidative 
type I fiber marker (MYH7) and lower expressions of glycolytic fiber type markers (MYH1, 
-2, -4) together with higher gene expressions of PGC1Į, MEF2c, and the myogenic markers 
(myoblast determination protein 1 (MYOD1) and myogenic factor 5 (MYF5)) (paper IV). 
In support of these results, MEF2 [323-325] and PGC1Į [78] are shown to regulate fiber 
type switching from glycolytic type II to oxidative type I fibers. In fact, muscle-specific 
knockout of MEF2c resulted in decreased proportion of oxidative fibers, while 
overexpression of MEF2c increased proportion of oxidative fibers [77]. Furthermore, we 
have previously shown that PGC1Į overexpression in human myotubes resulted in enhanced 
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lipid oxidative capacity and decreased gene expression of MYH2 [157]. MYOD and MYF5 
are important transcription factors that activate many downstream genes to initiate muscle 
cell differentiation to multinucleated myotubes [326]. Additionally, MYOD is also proposed 
to be implicated in the fast-fiber formation [327]. However, other studies have shown that 
neither knocking out the MYOD gene in mice [328] nor increased expression of MYOD 
after exercise in rat were involved in fiber-type transitions [329]. How a lack of PLIN2 can 
influence skeletal muscle differentiation/fiber type remodeling remains unclear, but it is 
likely that increased efflux of FAs may contribute to the observed metabolic shift in energy 
metabolism from utilization of glucose towards FAs and to the reduced expression of 
glycolytic and increased expression of oxidative muscle fiber type markers in PLIN2-/- 
myotubes (paper IV).  
 
Lipid storage and turnover 
Lipid droplets (LDs) are dynamic organelles resulting from the balance between storage and 
breakdown of TAG by lipases to generate FAs available for oxidation in the mitochondria 
[48]. Exercise has been found to increase lipid storage in skeletal muscle [330-332], but as 
we showed in paper III, EPS-stimulation had no effect on LDs. We (paper I) and others 
[99, 333] have shown that PLIN2 gene expression was increased after PPARį activation. 
However, as we showed in paper I, the increase in PLIN2 gene expression after PPARį 
activation by GW501516 was not accompanied with an effect on number of LDs or on 
lipolysis, indicating that a 2-fold increase in mRNA level observed after PPARį activation 
may not be accompanied by an increase in PLIN2 protein. Discrepancies between PLIN2 
mRNA and protein levels exist due to a rapid proteasomal degradation of PLIN2 proteins 
that are not bond to LDs [334]. On the other hand, by using PLIN2-/- myotubes, we 
demonstrated that PLIN2 plays an essential role in skeletal muscle lipid storage and turnover 
(paper IV). Similar to the earlier studies based on partly loss of PLIN2 [307, 335], we 
showed that a complete loss of PLIN2 in myotubes (paper IV) generated cells with reduced 
number of LDs and with less accumulated TAG. We also showed that lack of PLIN2 did not 
affect FA uptake rate across the plasma membrane or the amount of FA incorporated into 
LDs, but solely increased degradation of the TAG deposited within LDs by interfering with 
lipolysis. In agreement, earlier studies have shown that overexpression of PLIN2 in 
embryonic kidney cells limited the interaction of lipases with LDs [336] and higher lipolysis 
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in hepatocytes with combined PLIN2 and PLIN3 knockdown [335]. As shown in paper IV, 
inhibitors against ATGL or HSL had only an effect on LD accumulation in PLIN2-/- 
myotubes, suggesting that ATGL and HSL gained more access to LDs or increased in 
activity in cells lacking PLIN2. Consistent with this, higher TAG accumulation and lower 
lipolysis in skeletal muscles has been observed in ATGL-KO mice [337] whereas HSL-KO 
mice contains higher levels of DAG. [338]. In line with a functional role of PLIN2 as TAG 
protector, PLIN2-/- myotubes exposed to OA accumulated less DAG (paper IV), a finding 
that contradicts the previous report of increased incorporation of palmitic acid (PA) into 
DAG in C2C12 cells knocked down for PLIN2 [307]. As a functional redundancy is shown 
among some PLINs [335], the incomplete removal of PLIN2 protein in PLIN2 knocked-
down cells compared to complete removal of PLIN2-/- cells in paper IV likely contributes to 
these discrepancies. Additionally, the different types of labeled FAs used may also 
contribute as PA is accumulated to a lower extent into LDs than OA in myotubes [290].  
High levels of IMTG have been shown to correlate with insulin resistance [218-221]. On the 
other hand, insulin resistance has been shown to occur independently of changes in IMTG 
content, thus dissociating IMTG concentrations from insulin resistance [339]. Furthermore, 
increased storage of neutral lipids together with improved glucose metabolism and 
metabolic switching of the cells has been observed in studies with cultured human myotubes 
[64, 291, 340], suggesting that enhancing the partitioning of excess FAs toward storage is 
considered to be beneficial in preventing insulin resistance by limiting the accumulation of 
lipotoxic intermediates ([240, 341, 342] and reviewed in [239]). In accordance, as we 
showed in paper II, diabetic myotubes had lower lipid accumulation and FA incorporation 
into TAG and higher lipolysis without correspondingly increased FA oxidation compared to 
non-diabetic myotubes with similar BMI. Moreover, a higher DAG level in muscle has also 
been associated with obesity and insulin resistance [224, 225, 240, 267], whereas strategies 
that resulted in improved insulin sensitivity, on the other hand, did not consistently reduce 
DAG levels [124, 343, 344]. In accordance to this, we did not observe any differences in 
DAG content between obese diabetic myotubes and non-diabetic myotubes with similar 
BMI (paper II), confirming that it is not total DAG per se that is involved in insulin 
resistance. Furthermore, higher PLIN2 expression level in muscle has been shown to be 
associated with improved insulin sensitivity [241, 242]. On the other hand, PLIN2 loss-of-
function studies in liver or animal models showed inconsistent results on insulin sensitivity 
[335, 345-347]. As we showed in paper IV and also shown by others [307], complete or 
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partly removal of PLIN2 expression in skeletal muscle cells, respectively, had no impact on 
insulin-stimulated responses, suggesting that enhanced FA oxidation in PLIN2-/- cells act as 
a compensatory mechanism to handle a higher availability of FAs released from LDs. 
Furthermore, consistent with others [236], we observed neither differences in ATGL, HSL, 
PLIN2, and PLIN3 protein expression nor phosphorylation of HSL at serine 660 in the obese 
myotubes compared to diabetic myotubes with similar BMI despite functional changes in 
lipolysis (paper II). Thus, conflicting results were observed, suggesting complexity of the 
process. In fact, regulation of lipase activity is influenced by multiple steps, including 
phosphorylation of lipases, cofactors and PLIN proteins and complex movement of these 
different partners between the lipid droplets and the cytosol [48]. Further, increased 
expression of ATGL by PA in myotubes did not increase lipolysis, implying that content and 
activity are not directly linked [290].  
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Effects on insulin sensitivity 
Decreased insulin-stimulated glucose uptake into skeletal muscles is one of the hallmarks of 
T2D, and in paper II, we showed that myotubes from severely obese donors with T2D 
maintain their diabetic phenotype in culture. As stated above, it has been hypothesized that 
insulin resistance develops due to lower lipid accumulation and higher lipolysis without 
increased FA oxidation (paper II), processes which may lead to higher accumulation of 
lipotoxic intermediates that could interfere with insulin signalling. Consequently, much 
focus has been on the possibility of increasing lipid utilization with different approaches to 
avoid ectopic lipid accumulation in muscle [348-350]. However, as we showed in paper III, 
EPS improved insulin sensitivity in insulin-resistant myotubes from obese diabetic subjects 
without having impact on lipid oxidation or lipid accumulation. Furthermore, neither PPARį 
activation (paper I) nor ablation of PLIN2 (paper IV) affected insulin sensitivity measured 
as an effect on insulin-stimulated responses despite of improvement in lipid oxidative 
capacity. Similarly, others have shown that PPARį activation had no effect on insulin-
stimulated Akt phosphorylation [101]. Thus, conflicting results were observed, suggesting 
that insulin resistance in skeletal muscle is not solely dependent on increased lipid 
accumulation. Although a complete loss of PLIN2 in myotubes did not affect insulin-
stimulated responses, it generated cells with reduced expression of total Akt protein that may 
contribute to the reduced glucose metabolism observed in PLIN2-/- cells. However, the three 
different Akt isoforms (Akt1-3) are shown to have distinct roles, where Akt2 is specifically 
involved in the maintenance of glucose homeostasis [351, 352], and therefore remains to 
clarify which isoform(s) of the Akt proteins is reduced in PLIN2-/- cells. 
Of particular interest, the observed effect on insulin sensitivity in terms of improved insulin-
stimulated responses after EPS was more evident in myotubes from obese donors compared 
to lean donors (paper III), which is consistent with other studies [353, 354] reporting 
greater exercise-induced changes in insulin sensitivity in subjects who were more insulin-
resistant at baseline, and more evident in obese men compared to lean men [354]. This 
suggests that interventions to increase physical activity may be particularly effective at 
improving insulin sensitivity in population groups who are more insulin resistant or have an 
increased predisposition to insulin resistance. In addition, EPS alone had no effect on Akt 
phosphorylation in neither of the human donor groups (paper III), supporting the 
hypothesis of distinct pathways of exercise- and insulin-induced GLUT4 translocation [139, 
355-357]. Importantly, repeated contractions with EPS were able to restore insulin-
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stimulated Akt phosphorylation in insulin resistant myotubes (paper III), suggesting that 
exercise triggers an additional effect on the insulin cascade for enhancing the glucose uptake 
[358, 359]. In agreement, we have previously shown that EPS improved the reduced insulin-
stimulated glucose uptake observed in human myotubes after preincubation with 20 mM 
glucose (hyperglycemia) [250]. Similarly, others have shown that EPS rescued the reduced 
Akt phosphorylation observed in human myotubes after incubation with adipocyte-
conditioned medium [251]. Lack of EPS-induced increase in insulin sensitivity in myotubes 
from lean non-diabetic subjects could be explained by maximal responsiveness to insulin in 
those cells per se and limited capacity to respond further.  
In the present thesis, we have shown that EPS increased IL-6 mRNA expression in both lean 
and obese non-diabetic myotubes, whereas IL-6 mRNA expression was not affected in 
myotubes from obese diabetic subjects (paper III). In support, increase in IL-6 mRNA 
expression has been detected in muscle during exercise and in the post-exercise period in 
both lean and obese subjects [176, 360], whereas no effect on IL-6 mRNA levels were found 
in muscle biopsies from obese diabetic subjects [361] or in plasma from diabetic mice after 
in vivo exercise [362], suggesting an inherent abnormal IL-6 response in insulin-resistant 
skeletal muscle, also observed by others [363, 364]. Despite vast research on myokines the 
past decade, more research is needed in order to clarify whether there is an altered myokine 
response in skeletal muscles from subjects with disturbed metabolic status.  
 
Final considerations 
It should be noted that the myotubes used in this thesis were from donors with different age, 
both genders and different physical activity level, and this might have affected the observed 
results. For instance, plasma TAG values and BMI were higher and HDL lower in obese 
donors compared to lean donors (Table 2). Interestingly, we also observed that plasma TAG 
values correlated positively and HDL correlated negatively with the EPS-induced increase in 
insulin sensitivity reported in paper III (unpublished data), while BMI of the donors 
correlated negatively with the EPS-induced increase in lipid oxidation (paper III). In 
addition, we also observed that fasting plasma glucose levels (paper III) and age 
(unpublished data) of the donors correlated negatively with the EPS-induced increase in IL-6 
mRNA expression. Thus, responses in the myotubes may reflect the in vivo characteristics of 
the donor and might be influenced by the genetics or epigenetics of the donors.  
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Conclusively, oxidative capacity of the cells was increased with indications of a shift from 
glucose utilization towards FA after PPARį activation in human myotubes established from 
different donor groups (papers I and III) and in mice myotubes lacking PLIN2 (paper IV), 
while the EPS responses reflected the in vivo characteristics of the donors (paper III). We 
also conclude that PLIN2 is essential for balancing the pool of skeletal muscle LDs to avoid 
an uncontrolled hydrolysis of the intracellular TAG pool (paper IV), while increase of 
PLIN2 gene expression after PPARį activation was not accompanied with an effect on the 
number of LDs or on lipolysis (paper I). Moreover, data presented suggest that PLIN2 itself 
or its effect on lipid storage capacity may affect muscle fiber type remodelling (paper IV). 
Data presented also suggest a beneficial role of increased capacity for intramyocellular lipid 
accumulation, as this improves metabolic flexibility, which is associated with higher insulin 
sensitivity and increased glucose metabolism in human myotubes (paper II). On the 
contrary, EPS was able to improve insulin sensitivity and glucose oxidation in insulin-
resistant myotubes without having impact on lipid oxidation or lipid accumulation (paper 
III). Finally, neither increase in oxidative capacity of lipids after PPARį activation (paper 
I) nor ablation of PLIN2 (paper IV) had any impact on insulin-stimulated responses in 
skeletal muscle cells.  
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Abstract
About 80% of patients with type 2 diabetes are classified as overweight. However, only
about 1/3 of severely obese subjects have type 2 diabetes. This indicates that several se-
verely obese individuals may possess certain characteristics that protect them against type
2 diabetes. We therefore hypothesized that this apparent paradox could be related to funda-
mental differences in skeletal muscle lipid handling. Energy metabolism and metabolic flexi-
bility were examined in human myotubes derived from severely obese subjects without
(BMI 44±7 kg/m2) and with type 2 diabetes (BMI 43±6 kg/m2). Lower insulin sensitivity was
observed in myotubes from severely obese subjects with type 2 diabetes. Lipolysis rate
was higher, and oleic acid accumulation, triacylglycerol content, and fatty acid adaptability
were lower in myotubes from severely obese subjects with type 2 diabetes compared to se-
verely obese non-diabetic subjects. There were no differences in lipid distribution and
mRNA and protein expression of the lipases HSL and ATGL, the lipase cofactor CGI-58, or
the lipid droplet proteins PLIN2 and PLIN3. Glucose and oleic acid oxidation were also simi-
lar in cells from the two groups. In conclusion, myotubes established from severely obese
donors with established type 2 diabetes had lower ability for lipid accumulation and higher li-
polysis rate than myotubes from severely obese donors without diabetes. This indicates
that a difference in intramyocellular lipid turnover might be fundamental in evolving type
2 diabetes.
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Introduction
Overweight and obesity are strongly associated with insulin resistance and type 2 diabetes, and
the majority of subjects with type 2 diabetes are classified as overweight or obese [1]. However,
a study at the Morbid Obesity Center in Norway revealed that only 31% of the severely obese
patients enrolled for screening (BMI> 35 kg/m2) had type 2 diabetes [2]. Many organs are in-
volved in obesity-related type 2 diabetes, but skeletal muscle is one of the organs where insulin
resistance is most prominent.
Skeletal muscle uses both fat and carbohydrate as fuel, and fat predominates during fasting.
Metabolic flexibility is defined as the muscle’s ability to change between predominantly fatty
acid oxidation in the fasting state and carbohydrate oxidation in the fed state (reviewed in [3]).
This flexibility is reduced in insulin resistance and type 2 diabetes in vivo [4]. Treatments that
have positive effects on muscle metabolism, such as omega-3 fatty acids, have been observed to
increase both lipid accumulation and metabolic flexibility [5]. Interestingly, it has been ob-
served that muscle cells isolated from overweight/obese patients with or without type 2 diabetes
maintain these characteristics when grown in culture [6–8]. Studies performed on cultured
skeletal muscle cells (myotubes) from severely obese subjects are few [9–13], but the main find-
ings from these studies are that myotubes from the severely obese subjects have a reduced com-
plete fatty acid oxidation compared to cells from lean subjects [10, 11, 13], in addition to a
reduced mitochondrial content [11]. Other studies on myotubes from obese subjects with dia-
betes (BMI30 kg/m2) have shown reduced lipid oxidation associated with obesity and type 2
diabetes [14–16]. This reduced oxidation in obese/diabetic muscle has been attributed to im-
paired mitochondrial capacity [17] or lower mitochondrial content [18]. There are also reports
on unaltered and/or increased fatty acid oxidation in human skeletal muscle of obese or insulin
resistant individuals [19–21]. Increased fatty acid uptake [11] and partitioning of lipids towards
storage rather than oxidation was observed in myotubes from severely obese donors compared
to lean donors [10, 11]. Skeletal muscle store fat as triacylglycerols (TAG) in lipid droplets
(LDs) and lipid droplet-binding proteins (perilipins) coat and regulate lipid droplet biogenesis
and turnover, while adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) are
enzymes involved in lipolysis [22–24]. Increased intramyocellular lipid storage and/or levels of
intermediates in fatty acid metabolism have been shown to correlate with decreased insulin
sensitivity (reviewed in [25]). However, insulin signaling was also improved in presence of in-
creased lipid accumulation in human myotubes [26], and treatment of myotubes with metfor-
min has been shown to increase lipid accumulation in cells from lean individuals [8]. Finally,
athletes that are highly insulin sensitive have a higher content of lipid in skeletal muscle than
both overweight sedentary and overweight type 2 diabetic individuals [27]. Based on these
findings, new theories have emerged that focus on abnormal lipid storage or TAG lipolysis
rather than lipid storage per se (reviewed in [25]).
Myotubes in culture are known to maintain many phenotypic characteristics of the donor.
We wanted to study lipid storage and turnover capacity, as well as oxidation and metabolic
flexibility of myotubes from severely obese with and without type 2 diabetes, to see whether
lipid handling is inherently different between those who develop type 2 diabetes and those who
don’t.
Materials and Methods
Materials
Dulbecco’s modified Eagles medium (DMEM-Glutamax) low glucose with sodium pyruvate,
DMEM without phenol red, heat-inactivated FCS, penicillin-streptomycin and amphotericin B
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were from Gibco Invitrogen (Gibco, Life Technologies, Paisley, UK). SkGM-bulletkit was from
Lonza (Wakersville, MD, USA). Ultroser G was from PALL (St-Germain-en-Laye, France), in-
sulin (Actrapid) from NovoNordisk (Bagsvaerd, Denmark), BSA, L-carnitine, oleic acid (OA,
18:1, n-9), and triacsin C from Sigma (St.Louis, MO, US). [1–14C]oleic acid (2.15 GBq),
[9,10-3H]triolein (37 MBq) and D-[14C-(U)]glucose (107 MBq or 185 MBq) were from Perki-
nElmer NEN (Boston, MA, US), 2-[3H] deoxy-D-glucose (370 GBq) from American Radiola-
beled Chemicals Inc. (St.Louis, MO, US). 96-well Scintiplate was from Perkin Elmer (Boston,
MA, US), Corning CellBIND tissue culture plates and flasks from Corning Life-Sciences (Schi-
phol-Rijk, The Netherlands), glass bottom 6-well plates fromMatTek (Ashland, MA, US), and
Biocoat 25cm2 cell flask from BD Biosciences (Franklin Lakes, NJ, US). MitoTrackerRed FM,
Hoechst 33258, primers for TaqMan qPCR fromMolecular Probes, Invitrogen (Carlsbad, CA,
US). RNeasy minikit was from Qiagen (Venlo, The Netherlands), SYBR green from Applied
Biosystems (Warrington, UK) and Roche Diagnostics (Mannheim, Germany). TaqMan reverse
transcription kit reagents MicroAmp Optical Reaction Plate and High-Capacity cDNA revers
transcription kit were from Applied Biosystems (Warrington, UK), Agilent Total RNA isola-
tion kit from Agilent Technologies (Santa Clara, CA, US) and TRIzol Reagent from Invitrogen
Dynal AS (Carlsbad CA, US). Immun-Star WesternC kit, Mini-Protean TGX gels were from
BioRad (Copenhagen, Denmark). SPE column was fromMacherey-Nagel (Düren, Germany).
Donor characteristics
Muscle biopsies were obtained from subjects undergoing bariatric surgery at The Morbid Obe-
sity Center at Vestfold Hospital Trust, Norway. Biopsies were obtained after informed written
consent and approval by the Regional Committee for Medical and Health Research Ethics,
Oslo, Norway (approvement S-09078d). Blood samples were taken the day before biopsy re-
trieval or earlier (range 1 month to 2 years, median 1.5 years), due to practical reasons. The di-
agnosis of type 2 diabetes was based on fasting plasma glucose7.0 mM, HbA1c 6.5% and/
or the use of one or more antidiabetic drug. Of the 14 donors in the type 2 diabetic group, 6
were on metformin monotherapy, 2 on metformin and glimepiride, 1 on metformin in combi-
nation with rosiglitazone, 1 on pioglitazone monotherapy, 2 on insulin and 2 were untreated.
The donors did not receive medication on the day of surgery.
Cell culturing
Satellite cells were isolated fromM. obliquus internus abdominis and cultured as previously de-
scribed [28]. Experiments were performed after 7–8 days of differentiation and 100 μMOA
was added the last 24h of differentiation period. Protein concentration in each sample was de-
termined [29], and the results were standardized according to this value for each well. Not all
donors were included in each set of experiment, but 5–8 donors in each group were used, and
these were carefully matched with respect to age and BMI.
Deoxyglucose uptake
Myotubes were preincubated for 1h in serum-free DMEM-Glutamax (5.5 mM glucose) ± 100
nM insulin at 37°C before addition of [3H]deoxyglucose (37 kBq, 0.1 μM) in presence or ab-
sence of 100 nM insulin. Deoxyglucose uptake was measured for 1 h as previously described
[30].
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Scintillation proximity assay
Scintillation proximity assay (SPA) was performed as previously described [31] with [1–14C]
oleic acid (OA) (18.5 kBq, 100 μM) in medium without phenol red. Briefly, [14C]OA taken up
and accumulated by adherent cells will be concentrated close to the scintillator embedded in
the plastic bottom of each well (Scintiplate, Perkin Elmer) and provide a stronger signal than
the dissolved in the medium alone [32]. Lipid accumulation was monitored up to 24h with liq-
uid scintillation. Thereafter, the cells were washed twice with DPBS with 0.5% BSA, and incu-
bated in DPBS without radioactivity and liquid scintillation measurements were monitored
up to 3h. The decline in [14C]OA present in the cells in presence of triacsin C (total lipolysis,
10 μM) [33] was determined, before the remaining cell-associated (CA) radioactivity was as-
sessed. The decline in [14C]OA represent radioactivity released by the cells and provide a mea-
sure of lipolysis. Triacsin C inhibits long-chain fatty acyl-CoA synthetase and will therefore
inhibit, among other pathways, re-esterification.
Lipid distribution
Myotubes were incubated with 100 μMOA (18.5 kBq, 100 μM) for 24 h. Myotubes were then
washed twice with PBS and harvested with two additions of 125 μl distilled water. Cellular lip-
ids were extracted as described earlier [5]. Briefly, homogenized cell fractions were extracted,
lipids were separated by thin layer chromatography, and radioactivity was quantified by liquid
scintillation. The amount of neutral lipids was related to total protein concentrations.
Determination of total TAG content
Total TAG content in the cells were measured as previously described [34]. Briefly, lipids
were extracted in dichloromethane:methanol:water (2.5:2.5:2.1 (v/v/v)) in presence of internal
standards. Neutral lipids were separated over a SPE column (glass Chromabond pure silica,
200 mg), and neutral lipids were eluted with chloroform:methanol (9:1 (v/v)). The organic
phase was evaporated to dryness and dissolved in 20 μl of ethyl acetate. 1 μl of the lipid extract
was analyzed by gas-liquid chromatography.
TAG hydrolase activity assay
TAG hydrolase activity was measured on cell lysates as previously described [35]. [9,10-3H]
triolein was emulsified with phospholipids by sonication and used to determine TAG hydrolase
activity [5].
Live imaging
Myotubes were cultured on 6-well glass bottom plates coated with ECM gel. The cells were in-
cubated with Hoechst 33258 to stain nuclei, Bodipy 493/503 to stain neutral lipids and LDs
and MitoTrackerRed FM to stain mitochondria as previously described [5]. Images were ran-
domly taken in 25–36 positions per well. After gating out aggregates and dead cells, each pa-
rameter was determined from about 240 images per donor group (average of 38±4 nuclei per
image).
Substrate oxidation assay
Myotubes were cultured on 96-well CellBIND microplates. Substrates, [1–14C]OA (18.5 or 37
kBq, 5 or 100 μM) or D-[14C(U)]glucose (37 or 21.5 kBq, 111 or 200 μM/l) were given during
4h CO2 trapping with or without 5 mM glucose or 100 μM/l OA present. A 96-well UniFilter-
96 GF/B microplate was mounted on top of the CellBIND plate and CO2 production was
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measured in DPBS medium with 10 mMHEPES and 1 mM L-carnitine for 4h, as previously
described [32]. The sum of 14CO2 and remaining CA radioactivity reflects total cell uptake. In-
complete fatty acid oxidation, assessed as acid soluble metabolites (ASMs), was measured as
described [31].
Metabolic parameters
Suppresibility is the ability of the cells to decrease OA oxidation by acutely added glucose,
adaptability is the ability to increase OA oxidation with increasing OA concentration and sub-
strate-regulated flexibility is the ability to increase OA oxidation while changing from “fed”
(low fatty acid, high glucose) to “fasted” (high fatty acid, no glucose added) condition [5].
RNA isolation and mRNA expression
Total RNA from cells was isolated by Agilent Total RNA isolation kit according to the suppli-
er’s protocol. Total RNA from muscle biopsies was isolated using TRIzol and a clean-up proce-
dure was performed using RNeasy kit. RNA was reverse-transcribed with oligo primers using a
heat block (25°C for 10 min, 37°C for 1 h and 99°C for 5 min) or a PerkinElmer Thermal Cycler
9600 and qPCR was performed using an ABI PRISMT 7000 Detection System or a LightCycler
480 (Roche Diagnostic, Mannheim, Germany). Forward and reverse primers used at concen-
tration of 30 μM are presented in S1 Table. The transcription levels were normalized to the av-
erage of housekeeping genes GAPDH and RPLP0.
Immunoblotting
Total cell lysates prepared either in Laemmli or RIPA buffer containing 10 μl/ml protease in-
hibitor, 10 μl/ml phosphatase I inhibitor and 10 μl/ml phosphatase II inhibitor were electro-
phoretically separated, blotted to nitrocellulose membrane and incubated with antibodies
recognizing human total and phosphorylated Akt (Ser473), total HSL (#4107), Ser660 HSL
(#4126) and ATGL (#2138, all from Cell Signaling Technology, Beverley, MA, US), compara-
tive gene identification 58 (CGI-58) (#H00051099-M01, Abnova, Tapei, China), PLIN2
(#PA5-25042) and PLIN3 (#PA5-20272, Thermo Scientific, France), myosin slow muscle fiber
(MAB1628, Millipore Billerica, MA, US), total OXPHOSWB antibody cocktail (#110411,
Abcam), alpha-tubulin rabbit (#2144), GAPDH (#5174) and β-actin (#4970, all from Cell Sig-
naling Technology). Immunoreactive bands were visualized with enhanced chemiluminescence
(Chemidoc XRS, BioRad) and quantified with Gel-Pro Analyzer (version 2.0) software. Anti-
bodies against GAPDH, alpha-tubulin or β-actin were used to normalize the protein-antibody
signal.
Presentation of data and statistics
Two-tailed unpaired Student’s t-tests were performed to determine the difference between the
donor groups (GraphPad Prism 5.0, GraphPad Software Inc., San Diego, CA, US). For correla-
tion studies, Spearman correlation analysis was performed and Spearman coefficient, ρ, defines
the strength of the correlation (GraphPad Prism). Linear mixed model analysis (LMM, SPSS
20.0.0.1, IBM SPSS Inc., Chicago, IL, US) was used to compare the donors in time-course fatty
acid accumulation and lipolysis experiments (SPA). Values are reported as means ±SEM if not
stated otherwise. The value n represents the number of different donors used each with at least
duplicate samples. P< 0.05 was considered statistically significant.
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Results
Cell and donor characteristics
Selected characteristics of the muscle biopsy donors are presented in Table 1. Severely obese
without type 2 diabetes and severely obese with type 2 diabetes differed in fasting plasma glu-
cose and in HbA1c. There were no differences in plasma insulin, LDL, HDL, cholesterol, or tria-
cylglycerol (data not shown). The severely obese subjects with type 2 diabetes were on average
9 years older than the severely obese subjects with normal glucose tolerance. However, the dif-
ference in age could not explain the metabolic differences between the groups, assessed by mul-
tivariate analysis, and the duration of obesity in the two groups was not statistically different.
Physical activity level (self-reported) was also similar in the two groups (data not shown). Myo-
tube cultures established from the two groups of donors revealed no difference in protein or
mRNA expression of the marker for muscle fiber type I (MYH7, slow fiber type), determined
by immunoblotting and qPCR. There were no differences in mRNA expression of myosin
heavy chains in the biopsy samples either (data not shown).
Myotubes in vitromaintain their in vivo phenotype
To confirm that the myotubes maintained their diabetic phenotype in culture, insulin-stimulat-
ed glucose uptake and Akt phosphorylation (Ser473) were measured. Insulin-stimulated phos-
phorylation of Akt tended to be lower in myotubes from severely obese donors with type 2
diabetes compared to severely obese donors with normal glucose tolerance (Fig. 1A, p = 0.11).
Insulin-stimulated glucose uptake was abolished in myotubes from type 2 diabetics compared
to cells from non-diabetics (Fig. 1B, p = 0.01), implying a conserved insulin resistance in
cultured cells.
Reduced lipid accumulation in type 2 diabetic myotubes
To evaluate lipid turnover in the cells, accumulation of oleic acid (OA), distribution of lipids
and TAG hydrolase activity were determined. Without pre-incubation with OA, there were no
differences in lipid droplet number (LD) or total neutral lipid content in myotubes from se-
verely obese donors with or without T2D (Fig. 2A, p = 0.65, p = 0.81). Cellular accumulation of
[14C]OA was significantly lower in myotubes from type 2 diabetic subjects than in myotubes
from non-diabetics (Fig. 2B, p = 0.035). TAG measured after incubation of [14C]OA for 24 h
tended to be lower in myotubes from type 2 diabetic subjects than in myotubes from non-dia-
betics (Fig. 2C, p = 0.058) with no differences in free fatty acid (FFA, p = 0.22), diacylglycerol
(DAG, p = 0.97), cholesteryl ester (CE, p = 0.59) or phospholipids (PL, p = 0.10). In line with
this, total cell content of TAGmeasured after incubation of OA for 24 h was 50% lower in myo-
tubes from type 2 diabetic subjects than in myotubes from non-diabetics (Fig. 2D, p = 0.01).
Table 1. Donor characteristics for the donor group severely obese non-diabetics (nD) and severely obese with type 2 diabetes (T2D).
Age
(yrs)
BMI (kg/
m2)
Fasting Glucose
(mmol/l)
HbA1c
(%)
Insulin
(pmol/l)
LDL
(mmol/l)
HDL
(mmol/l)
Cholesterol
(mmol/l)
TG
(mmol/l)
n Male
nD 40 ± 7 44 ± 7 5.0 ± 0.5 5.4 ± 0.5 97 ± 51 2.8 ± 0.6 1.2 ± 0.2 4.7 ± 0.8 1.6 ± 0.5 15 4
T2D 49a ±
10
43 ± 6 7.6a ± 1.5 7.1a ±
1.6
78 ± 48 2.4 ± 1.0 1.1 ± 0.3 4.4 ± 1.3 1.8 ± 0.7 14 5
Mean ± SD are presented. aSigniﬁcantly different from nD. BMI; body mass index, HbA1c; glycosylated hemoglobin, HDL; high-density lipoprotein, LDL;
low-density lipoprotein, n; number, TG; triacylglycerol.
doi:10.1371/journal.pone.0119556.t001
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Although there was no difference in TAG hydrolase (TAGH) activity (Fig. 2D, p = 0.48),
the ratio DAG/TAG tended to be higher in the myotubes from type 2 diabetic subjects (27%,
p = 0.086).
Higher lipolysis rate in type 2 diabetic myotubes
To evaluate whether increased lipolysis rate could explain the lower accumulation and cell
content of TAG in type 2 diabetic myotubes, lipolysis rate with triacsin C (total lipolysis) was
measured. Indeed, lipolysis in presence of triacsin C was significantly higher in type 2 diabetic
myotubes than in non-diabetic myotubes (Fig. 3A, p = 0.046) and total lipolysis rate related
to cell-associated OA correlated positively with fasting plasma glucose levels of the subjects
(Fig. 3B). However, there were no differences in mRNA or protein expression of the lipases
HSL and ATGL and the lipase cofactor CGI-58, or the lipid droplet proteins PLIN2 and PLIN3
between the two groups (Fig. 3C, D). The fatty acid transporter CD36 was also equally express-
ed (Fig. 3C). These genes were also measured in presence of OA, but this revealed no further
differences between the groups (data not shown). No differences were observed in biopsy sam-
ples either (S2 Table). Phosphorylation of HSL at serine 660, which is associated with activation
of the lipase, was neither different between myotubes from the two groups (Fig. 3D).
Reduced mitochondrial staining but unchanged substrate oxidation
About 40% lower mitochondrial staining, measured as MitoTrackerRed intensity, was observed
in type 2 diabetic compared to non-diabetic myotubes (Fig. 4A, B, p = 0.03). Glucose and OA
oxidation (Fig. 4C, p = 0.5, p = 0.93, respectively) were not statistically different between the
Fig 1. Decreased insulin-stimulated glucose uptake and Akt phosphorylation in myotubes from severely obese donors with type 2 diabetes. (A)
Myotubes from severely obese non-diabetic donors (nD) and severely obese donors with type 2 diabetes (T2D) were incubated for 15 min with or without 100
nM insulin, before immunoblotting analysis with antibodies against phosho-Akt (Ser473) and total-Akt were performed. Data are shown as ratio phosho-Akt/
total Akt and related to unstimulated cells (n = 4–5). Immunoblotting from one representative experiment. (B) Glucose uptake was measured by [3H]
deoxyglucose with or without 100 nM insulin for 1 h. Basal glucose uptake was 251 ± 68 nmol/mg protein (nD) and 203 ± 34 nmol/mg protein (T2D). Data are
presented as mean ± SEM normalized to unstimulated cells, n = 7–8, #p< 0.05 versus basal, *p< 0.05 versus nD.
doi:10.1371/journal.pone.0119556.g001
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groups, neither were OA and glucose uptake nor incomplete OA oxidation (ASMs) (S1 Fig.).
Further, expressions of the two OXPHOS proteins, ATP synthase unit and Complex I subunit
NDUFB8, did not differ significantly between the groups either (p = 0.058 and p = 0.14, respec-
tively, Fig. 4D, E). We were not able to detect Complex II subunit 30 kDa, Complex III subunit
Core 2 and Complex IV subunit 2 of the OXPHOS protein complex. Challenging the cells with
Fig 2. Lower lipid accumulation in myotubes from severely obese donors with type 2 diabetes. (A)
Live imaging of lipid droplets and total neutral lipid content in myotubes from severely obese non-diabetic
donors (nD) and severely obese donors with type 2 diabetes (T2D). The cells were incubated for 15 min with
Hoechst 33258 to stain nuclei and Bodipy 493/503 to stain neutral lipids, n = 5. (B) [14C]OA accumulation
over 0–24 h. n = 5–6. (C) Lipid distribution measured as incorporation of [14C]OA into TAG, FFA, DAG, CE
and PL. Data are presented as % of total lipids in the cell, n = 5. (D) Total cell content of TAG and TAG
hydrolase (TAGH) activity in non-diabetic and type 2 diabetic myotubes after 24 h incubation with 100 μMOA.
Total cell content of TAG was 1.4±0.2 nmol/mg protein (T2D) and 3.0±0.6 nmol/mg protein (nD). TAGH was
3.7±0.3 nmol mg protein−1 h−1 (T2D) and 4.1±0.8 nmol mg protein−1 h−1 (nD) Data are presented relative to
mean values of non-diabetics, n = 6–7. *p<0.05 versus non-diabetic. CE, cholesteryl ester; DAG,
diacylglycerol; FFA, free fatty acid; OA, oleic acid; PL, phospholipid; TAG, triacylglycerol.
doi:10.1371/journal.pone.0119556.g002
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the mitochondrial uncoupler FCCP (carbonyl cyanide 4-trifluoromethoxy phenylhydrazone,
1 μM) or higher OA concentrations (600 μM) revealed no further difference between groups
(data not shown). Moreover, there were no differences between the groups in mRNA expres-
sion of essential genes in energy metabolism, e.g. carnitine palmitoyltransferase 1B (CPT1B),
pyruvate dehydrogenase kinase isozyme 4 (PDK4), peroxisome proliferator-activated receptor
gamma coactivator-1 alpha (PPARGC1A) and cytochrome C-1 (CYC1) (data not shown).
Metabolic flexibility
The metabolic flexibility parameters were determined as described before [5], and myotubes
derived from type 2 diabetics showed an about 30% lower adaptability for OA oxidation than
myotubes from non-diabetics, whilst the substrate-regulated flexibility and suppressibility pa-
rameters were not significantly different (Fig. 5, p = 0.02, p = 0.26, p = 0.45, respectively).
Fig 3. Higher lipolysis rate in myotubes from severely obese donors with type 2 diabetes. (A) Total lipolysis (with triacsin C) after 24 h incubation with
[14C]OA in non-diabetic (nD) and type 2 diabetic myotubes (T2D) n = 5–6. (B) Fasting plasma glucose levels correlated positively with total lipolysis rate, n =
11 (C) mRNA expression of hormone-sensitive lipase (HSL), adipose triglyceride lipase (ATGL), perilipin 2 (PLIN2), perilipin 3 (PLIN3) and the fatty acid
transporter CD36. Data are presented relative to mean values of non-diabetics, n = 6–10. (D-E) Protein expression of HSL, ATGL, comparative gene
identification 58 (CGI-58), PLIN2 and PLIN3 and phosphorylation of HSL at serine 660 (HSL Ser660) after 24h incubation with 100 μMOA. (D) Two
representative blots are shown. Data are presented relative to mean values of non-diabetics, n = 5.
doi:10.1371/journal.pone.0119556.g003
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Fig 4. Lower mitochondrial staining of myotubes from severely obese donors with type 2 diabetes.Myotubes from severely obese non-diabetic
donors (nD) and severely obese donors with type 2 diabetes (T2D) were stained with MitoTrackerRed (mitochondria) and Hoechst 33258 (nuclei). (A)
Representative images after 24h incubation with 100 μM oleic acid (OA). Blue is nuclei and red is mitochondria. Magnification is 1:20, scale bar represents
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Discussion
Disturbances in skeletal muscle lipid metabolism are clearly associated with insulin resistance
and type 2 diabetes. In the present study, we wanted to examine lipid handling in myotubes
50 μm. (B) Mitochondrial staining related to number of nuclei per 100 0000 AU. Myotubes were incubated with or without 100 μM oleic acid (OA). Mean±SEM
are presented related to number of nuclei, n = 5, *p<0.05 versus non-diabetics. (C)OA oxidation or glucose oxidation were measured in presence of [14C]OA
(18.5 kBq, 100 μM) or [14C]glucose (18.5 kBq, 200 μM) for 4h. Data are presented as mean±SEM, n = 7. AU, arbitrary units. (D-E) Protein expressions of ATP
synthase subunit and Complex I subunit NDUFB8. Protein samples were harvested and analyzed as described in Materials and Methods, and expression
levels were normalized to alpha-tubulin. (D)Representative Western blots from one experiment. (E) Protein expressions of ATP synthase subunit and
Complex I subunit NDUFB8 related to alpha-tubulin. Data are presented as mean±SEM, n = 5–8.
doi:10.1371/journal.pone.0119556.g004
Fig 5. Metabolic flexibility parameters in myotubes derived from severely obese non-diabetic donors
(nD) and severely obese donors with type 2 diabetes (T2D). Calculations of metabolic parameters are
performed as described [5]. Suppressibility is (1- oxidation of 100 μMOA at 5 mM glucose/oxidation of
100 μMOA at no glucose added)*100%, adaptability is oxidation of 100 μMOA/oxidation of 5 μMOA, and
substrate-regulated flexibility is oxidation of 100 μMOAwithout glucose added/oxidation of 5 μMOA at 5 mM
glucose. Linear mixed model was performed for adaptability and suppressibility, while unpaired two-tailed
t-test was performed for substrate-regulated flexibility, *p<0.05 versus non-diabetics, n = 7–8.
doi:10.1371/journal.pone.0119556.g005
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isolated from severely obese that have developed type 2 diabetes and severely obese with nor-
mal glucose tolerance to see whether there are fundamental differences. We observed that myo-
tubes established from severely obese type 2 diabetic donors had higher lipolysis rate and were
less able to accumulate fatty acids than myotubes from severely obese with normal glucose tol-
erance. In line with this, TAG content was lower in myotubes from type 2 diabetic donors but
there were no significant differences in lipid distribution into FFA, DAG, CE or PL. There were
no differences in fatty acid and glucose oxidation either. Although the diabetic cells had lower
mitochondrial content as assessed by Mitotracker, expression levels of the OXPHOS proteins
did not differ significantly between the groups. Further, diabetic cells showed less ability to in-
crease fatty acid oxidation with increased oleic acid availability (adaptability). We also con-
firmed that myotubes derived from severely obese donors with T2D had lower insulin
sensitivity compared to cells from non-diabetic donors, a trait apparently conserved from the
in vivo situation.
There are numerous studies showing an association between insulin resistance and in-
creased lipid accumulation in skeletal muscle of type 2 diabetic subjects [25, 36]. However,
there are also indications that this association is not solely due to ectopic lipid accumulation,
but rather caused by dysregulation of lipolysis and/or lipid turnover [25, 27, 37]. Lower lipid
accumulation and higher lipolysis without correspondingly increased fatty acid oxidation, as
observed in type 2 diabetic myotubes in this study, could contribute to accumulation of lipo-
toxic intermediates, which are reported to interfere with insulin signaling [38–40], (reviewed in
[25]). Although we could not observe any differences in DAG content, the ratio of DAG/TAG
tended to be higher in type 2 diabetic myotubes. In correspondence with this, higher DAG
level in muscle has been associated with obesity and insulin resistance in both rats and humans
[39, 41], while muscle ceramides are also elevated in lean or obese insulin resistant humans
and rats [41]. Although TLC is a sensitive method, we cannot exclude that small differences
that we were not able to detect, in for instance DAG or other lipid intermediates could mediate
important signaling effects.
We observed lower lipid accumulation and higher lipolysis rate in myotubes from severely
obese type 2 diabetic donors without any difference between cells from the two groups with re-
spect to protein and mRNA expression levels of CD36, PLINs, ATGL, HSL and CGI-58. Re-
duced protein expression of the lipase HSL has previously been shown in obese insulin-
resistant subjects [24, 42], and increased protein levels of ATGL in both obese subjects with
type 2 diabetes [22] and obese non-diabetic subjects [24]. However, no apparent changes in li-
pases and PLIN proteins were observed in the present study despite functional changes in lipol-
ysis. The regulation of lipase activity is a complex process regulated at multiple steps, including
phosphorylation of lipases and PLIN proteins and complex movement of these different part-
ners between the lipid droplets and the cytosol [43]. HSL activity is probably mostly regulated
by phosphorylation [43]. However, we were not able to detect any differences in HSL660 phos-
phorylation in myotubes from the two donor groups, but other phosphorylation sites, not stud-
ied here, may be involved. Recently, we observed that increased expression of ATGL by
palmitic acid in myotubes, did not increase lipolysis, implying that content and activity are not
directly linked [31]. ATGL can also be phosphorylated, although its activity appears mainly
controlled by the co-activator CGI-58 [43]. Exactly how lipolysis rate is regulation by PLINs is
not known, but PLIN2 has been found co-localized with HSL after epinephrine stimulation,
and PLIN5 is suggested to channel fatty acids to the mitochondria after lipolysis [43]. In accor-
dance with a recent observation in myotubes from obese individuals with or without type 2 dia-
betes [44], we could not detect any change in expressions of PLIN2 and PLIN3, and further
investigation on how PLINs and lipases interact is needed.
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TAG content of type 2 diabetic myotubes was about 50% of the content in non-diabetic con-
trols after 24 h incubation with OA. This difference can possibly be explained by increased lipo-
lytic rate, combined with less lipid accumulation. However, there might also be differences in
TAG synthesis, for instance DGAT activity or in lipid uptake. A complete picture is difficult to
interpret. CD36 expression was similar as well as fatty acid uptake, assessed as cell associated OA
after 4 h (data not shown), and Sparks et al. showed very recently that DGAT-activity did not dif-
fer between myotubes from obese males with T2D and BMI and age matched controls [44]. Alto-
gether, we have documented disturbed lipid handling, but still the explanation is puzzling.
In addition to lipid turnover, metabolic flexibility was also impaired in myotubes derived
from type 2 diabetic donors, assessed as reduced adaptability for fatty acid oxidation. In support,
lower ability to increase oxidation with increasing fatty acid concentration in myotubes from
overweight/obese type 2 diabetics [8] and reduced metabolic flexibility in vivo in insulin resistant
muscle [4] compared to healthy lean donors have been reported. The combination of decreased
adaptability and higher lipolysis rate might be unfavorable and likely contribute to an abnormal
intracellular lipid profile. Interestingly, we found lower mitochondrial staining in myotubes from
severely obese with type 2 diabetes compared to cells from severely obese non-diabetic donors, in
accordance with earlier studies showing lower mitochondrial content in insulin resistant muscle
[17, 45]. This occurred despite no differences in fatty acid oxidation, nor in the OXPHOS protein
expression or mRNA expression of CYC1, PPARGC1A, CPT1B or PDK4 in myotubes from se-
verely obese donors with type 2 diabetes compared to cells from severely obese non-diabetic do-
nors. The focus in recent years has been directed towards a mitochondrial deficiency/dysfunction
in relation to development of type 2 diabetes, and several studies conclude that the observed re-
duced mitochondrial function in type 2 diabetes is due to, and secondary to, a lower mitochon-
drial content in muscle (reviewed in [46]). Although one might expect that oxidation and
mitochondrial content are positively associated, an inverse correlation between mitochondrial
content and degree of complete lipid oxidation has been observed in myotubes [47].
Increasing age is related to elevated insulin resistance and so is increasing obesity related to
aging. The subjects with type 2 diabetes in this study were in average older than the non-diabet-
ic subjects, however, the duration of obesity did not differ and age per se could not explain the
metabolic differences. It is also hypothesized that obesity and inactivity rather than age per se is
the primary determinant of age-related declines in insulin sensitivity [48, 49].
Altogether, our results show that there are retained differences in cells cultured from sub-
jects with and without diabetes. This is in accordance with many previous observations [6, 14,
44]. Actually, how these differences are conserved from the in vivo to the in vitro situation is
not known. Most studies have failed to explain this by genetic polymorphism, but a possibility,
yet undetected, is that epigenetic changes could accumulate in vivo and be transmitted to in the
cultured cells, causing a diabetic phenotype.
In conclusion, myotubes established from severely obese subjects with established type 2 di-
abetes had lower ability for lipid accumulation and higher lipolysis rate than myotubes from se-
verely obese donors without diabetes. Our hypothesis is that by storing more lipids as
triacylglycerol, the formation of lipotoxic intermediates that could interfere with insulin signal-
ing may be prevented. Higher lipolysis not followed by a higher fatty acid oxidation, in combi-
nation with lower adaptability and lower mitochondrial content could contribute to a diabetic
metabolic profile.
Supporting Information
S1 Fig. Oleic acid and glucose uptake and acid soluble metabolites (ASM) in myotubes de-
rived from severely obese non-diabetics (nD) and severely obese diabetics (T2D). (A)
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Cellular uptake of oleic acid and glucose, assessed as the sum of cell associated and CO2-
trapped radioactivity after 4 h, n = 7. (B) Incomplete fatty acid oxidation, detected as ASM,
were assessed after incubation of 100 μM or 600 μM oleic acid (OA) for 24 h, n = 5. Data are
presented as mean ± SEM.
(TIF)
S1 Table. Primer sequences used in real time RT-PCR.
(PDF)
S2 Table. mRNA expression in biopsies for the donor groups severely obese non-diabetics
(nD) and severely obese with type 2 diabetes (T2D). Data are presented as fold change to the
average of two housekeeping genes (GAPDH and RPLP0). Mean ± SEM are presented for n = 7
donors per group.
(PDF)
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(A) Cellular uptake of oleic acid and glucose, assessed as the sum of cell associated and CO2-
trapped radioactivity after 4 h, n = 7. (B) Incomplete fatty acid oxidation, detected as ASM, were 
assessed after incubation of 100 μM or 600 μM oleic acid (OA) for 24 h, n = 5. Data are 
presented as mean ± SEM. 
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